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Résumé
L’endothéline-1 (ET-1) est un peptide vasoactif extrêmement puissant qui possède une 
forte activité mitogénique dans les cellules du muscle lisse vasculaire (VSMCs). Il a été 
démontré que l’ET-1 est impliquée dans plusieurs maladies cardio-vasculaires, comme 
l’athérosclérose, l'hypertension, la resténose après l'angioplastie, l’insuffisance cardiaque 
et l'arythmie. L’ET-1 exerce ses effets via plusieurs voies de signalisation qui incluent le 
Ca2+, les protéines kinases activées par les mitogènes (MAPKs) y compris les kinases 
régulées par les signaux extracellulaires (ERK1/2) et la voie de la phosphatidylinositol 3-
kinase (PI-3K)/protein kinase B (PKB). Plusieurs études ont démontré que les dérivés 
réactifs de l'oxygène (ROS) peuvent jouer un rôle important dans la signalisation 
d’ERK1/2 et de PKB induite par plusieurs facteurs de croissance et hormones. 
Nous avons précédemment montré que l'ET-1 produit des ROS qui agissent comme 
médiateur de la signalisation cellulaire induite par l’ET-1. Le peroxyde d’hydrogène 
(H2O2), une molécule qui appartient à la famille des ROS, peut activer les voies de la 
MAPK et de la PKB dans les VSMCs. Par ailleurs, nos résultats suggèrent également que 
le Ca2+ et la calmoduline (CaM) sont essentiels pour la phosphorylation d’ERK1/2, de 
p38 et de PKB induite par le H2O2 dans les VSMCs. La Ca2+/CaM-dependent protein 
kinases II (CaMKII) est une sérine/thréonine protéine kinase multifonctionnelle activée 
par le Ca2+/CaM. Il a été montré que la CaMKII est impliquée dans les voies de 
signalisation induite par le H2O2 dans les cellules endothéliales. Cependant, le rôle de la 
CaMKII dans la phosphorylation d’ERK1/2, de PKB et de la proline-rich tyrosine kinase 
2 (Pyk2) induite par l’ET-1 et le H2O2, de même que son rôle dans l’effet hypertrophique 
et prolifératif de l’ET-1 dans les VSMCs demeure inexploré.  
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Le monoxyde d’azote (NO) est une molécule vasoactive impliquée dans la régulation de 
plusieurs réponses hormonales. Le NO peut moduler la signalisation contrôlant la 
croissance cellulaire induite par plusieurs agonistes d’où son rôle protecteur dans le 
système vasculaire.  
Des études ont montré que le NO peut inhiber la voie de Ras/Raf/ERK1/2 et la voie de 
PKB induite par le facteur de croissance endothélial (EGF) et l’angiotensine II (Ang II). 
Beaucoup d’autres travaux ont mis en évidence un cross-talk entre les voies de 
signalisation activées par l’ET-1 et le NO. La capacité du NO à inhiber la signalisation 
intracellulaire induite par l’ET-1 dans les VSMCs demeure inconnue. Le travail présenté 
dans cette thèse vise à déterminer le rôle du système Ca2+-CaM-CaMKII dans la 
phosphorylation d’ERK1/2, de PKB et de Pyk2 induite par l’ET-1 et le H2O2 ainsi que 
son rôle dans la croissance et la prolifération cellulaire induites par l’ET-1 dans les 
VSMCs. Nous avons également testé le rôle du NO dans la phosphorylation d’ERK1/2, 
de PKB et de Pyk2 ainsi que la synthèse protéique induite par l’ET-1. 
 
Dans la première partie de notre étude, nous avons examiné le rôle de la CaMKII dans la 
phosphorylation d’ERK1/2 et de PKB induite par l’ET-1 dans les VSMCs en utilisant 
trois approches différentes i.e. l'usage d'inhibiteurs pharmacologiques, un peptide auto-
inhibiteur de la CaMKII  (CaMKII AIP) et la technique de siRNA. Nous avons démontré 
que la CaMKII est impliquée dans la phosphorylation d’ERK1/2 et de PKB induite par 
l’ET-1 dans les VSMCs. Des études précédentes ont montré à l’aide d’inhibiteurs 
pharmacologiques comme le KN-93 que l'Ang II et les agents induisant une 
augmentation de la concentration en Ca2+ intracellulaire comme l’ionomycine, 
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provoquent la phosphorylation d’ERK1/2 via la CaM dans les VSMCs. Cependant, en 
utilisant différentes approches, nos études ont montré pour la première fois une 
implication de la CaMKII dans la phosphorylation d’ERK1/2 et de PKB induite par l’ET-
1 dans les VSMCs. Nous avons également rapporté pour la première fois, un rôle crucial 
de la CaMKII dans la pathophysiologie vasculaire associée à l’ET-1 puisque l’activation 
de la CaMKII joue un rôle important dans l’hypertrophie et la croissance cellulaire. 
Dans la deuxième partie, à la lumière des études précédentes qui montraient que les ROS 
agissent comme médiateurs de la signalisation induite par l’ET-1 dans les VSMCs, nous 
avons examiné si la CaMKII est également impliquée dans l’activation des voies 
d’ERK1/2 et de PKB induite par le H2O2. En utilisant des approches pharmacologiques et 
moléculaires, nous avons montré, comme pour l’ET-1, que la CaMKII joue un rôle 
critique en amont de la phosphorylation d’ERK1/2, de PKB et de Pyk2 induite par le 
H2O2. 
Nous avons précédemment montré que la transactivation du récepteur de type I de 
l’insulin-like growth factor (IGF-1R) est nécessaire à l’activation de PKB induite par le 
H2O2. Pour cette raison, nous avons examiné l'effet de l'inhibition de la CaMKII par 
l’inhibiteur pharmacologique ou par le knock-down de la CaMKII sur la phosphorylation 
d’IGF-1R induite par le H2O2. Les résultats démontrent que la CaMKII joue un rôle 
critique en amont de la phosphorylation d’ERK1/2, de PKB et d’IGF-1R induite par le 
H2O2.  
Dans la troisième partie de notre étude, nous avons également examiné le mécanisme 
moléculaire par lequel le NO exerce ses effets anti-mitogéniques et anti-hypertrophiques 
dans la signalisation induite par l’ET-1. En testant l'effet de deux différents donneurs de 
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NO (S-nitroso-N-acetylpenicillamine (SNAP), sodium nitroprusside (SNP)) et  un 
inhibiteur de NO synthase, le N (G)-nitro-L-arginine methyl ester (L-NAME) dans la 
phosphorylation d’ERK1/2, de PKB et de Pyk2 induite par l’ET-1, nous avons observé 
que le NO a un effet inhibiteur sur la signalisation induite par l’ET-1 dans les VSMCs. 
Par ailleurs, le 8-Br-GMPc, un analogue du GMPc, a un effet similaire à celui des deux 
donneurs du NO, tandis que l’oxadiazole quinoxaline (ODQ), un inhibiteur de la 
guanylate cyclase soluble, inverse l'effet inhibiteur du NO. Nous concluons que le NO 
diminue la phosphorylation d’ERK1/2, de PKB et de Pyk2 induite par l’ET-1 d’une 
manière dépendante du GMPc. Le NO inhibe aussi les effets hypertrophiques de l’ET-1 
puisque le traitement avec le SNAP diminue la synthèse des protéines induite par l’ET-1.  
 
En résumé, les études présentées dans cette thèse démontrent que l’ET-1 et le H2O2 sont 
des activateurs de la phosphorylation d’ERK1/2, de PKB et de Pyk2 dans les VSMCs et 
que la CaMKII s’avère nécessaire pour ce processus, en agissant en amont de l’activation 
de IGF-1R induite par le H2O2 dans les VSMCs. Elles montrent également que le NO 
inhibe la phosphorylation d’ERK1/2, de PKB et de Pyk2 induite par l’ET-1.  Enfin, nos 
travaux  suggèrent aussi que l’activation de la CaMKII stimule la synthèse des protéines 
et de l’ADN induites par l’ET-1 alors que le NO inhibe la synthèse des protéines induite 
par ET-1. 
Mots clés: Endothéline ; Peroxyde d'hydrogène ; CaMKII ; Monoxyde d’azote ; Système 
vasculaire ; PKB; ERK1/2; IGF-1R; Hypertrophie.  
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Abstract
Endothelin-1 has emerged as an extremely potent vasoactive peptide exhibiting 
potent mitogenic activity in vascular smooth muscle cells (VSMCs). A critical role of 
ET-1 in many cardiovascular diseases, such as atherosclerosis, hypertension, restenosis 
after angioplasty, heart failure and arrhythmia has been suggested. ET-1 exerts its effects 
through multiple signaling pathways which include Ca2+, mitogen-activated protein 
kinases (MAPKs) including extracellular signal-regulated kinases 1/2 (ERK1/2) and 
phosphatidylinositol 3-kinase (PI-3K)/protein kinase B (PKB)/Akt pathways. Several 
studies have also demonstrated that reactive oxygen species (ROS) may play an 
important role in mediating the signals of several growth factors and peptides hormones 
linked to these pathways. We have previously reported that ET-1 generates ROS which 
mediates ET-1-induced signaling. H2O2, an important ROS molecule, activates both 
MAPKs and PKB signaling in VSMCs. In addition, we have also suggested that Ca2+ and 
CaM are essential to trigger H2O2-induced ERK1/2, p38 and PKB phosphorylation in A-
10 VSMCs. Ca2+/calmodulin (CaM)-dependent protein kinase II (CaMKII) is a 
multifunctional serine/threonine protein kinase which is believed to transduce the 
downstream effects of Ca2+/CaM, and has been shown to be involved in H2O2-induced 
signaling in endothelial cells. However, a role of CaMKII in mediating ET-1 and H2O2-
induced ERK1/2, PKB, Pyk2 phosphorylation, as well as its effect on hypertrophic and 
proliferative responses of ET-1 in VSMCs remains unexplored. Interestingly, a role of 
CaMKII in several cardiovascular diseases has been reported and studies showing that 
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pharmacological inhibition of CaMKII, by using KN-93, prevent arrhythmic activity 
improved vascular dysfunction in diabetes or in Ang II-induced hypertension.  
Nitric oxide (NO) is also an important reactive species and vasoactive molecule 
involved in the regulation of several hormone-mediated responses. NO has been 
suggested to modify growth-promoting signaling events and thus may serve as a vascular 
protective agent. Studies have shown that NO can attenuate EGF and Ang II-induced 
Ras/Raf/ERK1/2 as well as increase in PKB phosphorylation signaling pathways. There 
is also evidence for a potential cross-talk between ET-1 and NO, however not much 
information on the ability of NO to modify ET-1-induced signaling in VSMCs is 
available. Therefore, the work presented in this thesis has investigated the role of 
CaMKII system in ET-1 and H2O2-induced ERK1/2, PKB and Pyk2 phosphorylation, as 
well as in cell growth and proliferation evoked by ET-1 in VSMCs. We also investigated 
the role of NO in ET-1-induced ERK1/2, PKB and Pyk2 phosphorylation as well as 
protein synthesis.   
 In the first part of our studies, by using three different approaches, i.e. use of 
pharmacological inhibitors, a CaMKII AIP (autoinhibitor peptide) and siRNA techniques, 
we have investigated the involvement of CaMKII in ET-1-induced ERK1/2 and PKB 
phosphorylation in A-10 VSMC. We have demonstrated that CaMKII mediates the effect 
of ET-1 on ERK1/2 and PKB phosphorylation in A-10 VSMC.  
By using pharmacological inhibitor alone such as, KN-93, earlier studies have reported 
that AngII and Ca2+ elevating agents, such as ionomycin, exert their effects on ERK1/2 
phosphorylation via CaM-dependent pathways in VSMC. However, by using multiple 
approaches, our studies, have provided the first evidence to suggest an involvement of 
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CaMKII in mediating the effect of ET-1 on ERK1/2 and PKB phosphorylation in A-10 
VSMC. We have also reported for the first time, a crucial role of CaMKII in vascular 
pathophysiology related to ET-1 by regulating the growth and hypertrophic events by 
using the technique of [3H]leucine and [3H]thymidine incorporation. 
In the second part, in view of earlier studies showing that ROS mediates ET-1-induced 
signaling events in VSMC, we have also investigated if CaMKII is also implicated in 
H2O2-induced activation of ERK1/2 and PKB pathways. By using both pharmacological 
and molecular approaches, we show that similar to ET-1, CaMKII serves as a critical 
upstream component in triggering H2O2-induced ERK1/2, PKB and Pyk2 
phosphorylation in VSMC. Furthermore, since we have previously reported that IGF-1R 
transactivation is needed for H2O2-induced PKB activation, we have investigated the 
effect of CaMKII inhibition and knocking-down on IGF-1R phosphorylation evoked by 
H2O2. Taken together, these results demonstrate that CaMKII plays a critical upstream 
role in mediating the effect of H2O2 on ERK1/2, PKB and IGF-1R phosphorylation.  
In the third part of our studies, we have investigated the molecular mechanism by which 
NO exerts its anti-mitogenic and anti-hypertrophic effect on ET-1-induced signaling. By 
testing the effect of two different NO donors (SNAP and SNP) and L-NAME, an 
inhibitor of NO synthase, in ET-1-induced ERK1/2, PKB and Pyk2 phosphorylation, we 
observed that NO has an inhibitory effect in ET-1-induced signaling in VSMC. In 
addition, 8-Br-cGMP, an analogue of cGMP, exerted similar effect to that of NO donors 
whereas, oxadiazole quinoxalin (ODQ), an inhibitor of soluble guanylyl cyclase (sGC), 
reversed the inhibitory effect of NO. We conclude that NO, in a cGMP-dependent 
manner, attenuated ET-1-induced phosphorylation of ERK1/2, PKB and Pyk2 and also 
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antagonized the hypertrophic effects of ET-1, since SNAP treatment decreased the 
protein synthesis induced by ET-1. 
 
In summary, the studies presented in this thesis demonstrate that both ET-1 and 
H2O2 induce ERK1/2, PKB and Pyk2 phosphorylation in VSMC and CaMKII activation 
is required for these events. We have also shown that CaMKII phosphorylation is 
upstream of H2O2-induced IGF-1R transactivation in VSMC. We have also provided 
evidence that NO attenuates ET-1-induced ERK1/2, PKB and Pyk2 phosphorylation. 
Finally, we have established that CaMKII activation stimulates ET-1-evoked protein and 
DNA synthesis, yet NO attenuates protein synthesis induced by ET-1.   
 
Keywords : Endothelin; Hydrogen peroxide; CaMKII; Nitric oxide; Vascular; Protein 
Kinase B; Extracellular Signal-Regulated Kinase1/2; IGF-1R; Growth.  
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CHAPTER 1
 
INTRODUCTION 
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1 Endothelin  
Endothelin (ET) was discovered by Yanagisawa and co-workers in 1988 (1) 
who also characterized and cloned it from porcine aortic endothelial cells (1). ET is one 
of the most potent vasoconstrictors that exhibits inotropic and mitogenic properties, 
influences salt and water homeostasis and stimulates the renin-angiotensin-aldosterone 
as well as sympathetic system (2-4). The overall effect of ET is usually to increase 
vascular tone and blood pressure. ET is believed to play an important role in vascular 
remodelling associated with experimental and human hypertension (4;5). Increased 
vascular smooth muscle cell (VSMC) hypertrophy, migration and proliferation are 
among the key events that contribute to remodeling of the vasculature associated with 
cardiovascular diseases. ET-1 exerts its physiological action by activating several signal 
transduction pathways linked to cellular hypertrophy, growth, migration and 
proliferation in several cell types including cardiomyocytes (6;7), kidney mesangial 
cells (8), and in the vascular system (9;10).  
 
1-1 Structure of ETs  
ET is a 21 amino acid peptide which exists in at least three isoforms, ET-1, ET-
2 and ET-3 (11). All ET isopeptides share a common structure, two disulfide bonds 
(Cys1-Cys15 and Cys3-Cys11), a cluster of three polar charged side chains on amino acid 
residues 8-10 and a hydrophobic C-terminus (residues 16-21) containing the aromatic 
indole side chain at Trp21 (Fig. 1). ET-2 contains two amino acid substitutions (Trp6-
Leu7) and shares 90% sequence homology with ET-1. ET-3 contains six amino acid  
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substitutions (Thr2, Phe4-Thr5-Tyr6-Lys7 and Tyr14) and shares 71% sequence 
homology with ET-1 and ET-2. The hydrophobic C-terminus of ET is essential for its 
bioactivity, as well as the loop configuration (12). Among the three ETs, ET-1 is the 
most important isopeptide in the vasculature (Fig. 1).  
 
1-2 Regulation and sites of generation of ET-1 
1-2-1 Regulation 
Generation of ET-1 is increased by several factors, including vasoactive hormones, 
growth factors, hypoxia, shear stress, lipoproteins, free radicals, endotoxin and 
cyclosporin (13) (Fig 2) whereas factors that increase intracellular level of cyclic 
guanosine monophosphate (cGMP), including endothelium-derived nitric oxide, 
nitrovasodilators, natriuretic peptides, heparin and prostaglandins (13) are known to 
inhibit the production of ET-1 (Table1 shows a list of factors that influence ET-1 
secretion). Each member of the ET family is represented by a separate gene that 
encodes a specific precursor for the mature isoform (11). In the 5' flanking region there 
are binding sites for activating protein 1 and nuclear factor 1, which mediate the 
induction of mRNA for ET-1 by angiotensin II (Ang II) and transforming growth 
factor-, respectively (14). The 3' flanking region of the mRNA contains adenine-
uracil-rich sequences that mediate selective destabilization of preproendothelin-1 
mRNA, accounting for its relatively short biological half life of 15 min.  
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1-2-2 Site of generation 
Endothelial cells express a high level of mRNA for preproendothelin-1 and intracellular 
converting enzyme. Compared to other cell types, endothelial cells are the major site of 
ET-1 generation (11). ET-1 is also produced by the heart, kidney, posterior pituitary 
and central nervous system (13). Human aortic vascular smooth muscle cells also 
express mRNA for ET-1, although its production is about 100-fold less than that in 
endothelial cells. Limited amounts of ET-2 are produced in endothelial cells, heart and 
kidney (15;16). ET-3 appears to be expressed in the endocrine, gastro-intestinal and 
central nervous systems, but not in endothelial cells (13) 
 
1-3 Biosynthesis of ET 
The initial product of the human ET-1 gene is preproendothelin-1, a 212 amino acid 
peptide (Fig.2). Proendothelin-1 is formed after removal of a short secretory sequence, 
and is then cleaved by furin to generate a 38 amino acid peptide, bigET-1 (1). BigET-1 
does not appear to have any direct actions (17). The formation of mature ET-1 requires 
cleavage of bigET-1 by one of several unique ET converting enzymes (ECE). This 
family of metalloproteases is related to neutral endopeptidase-24.11 and Kell protein, 
but not to Ang II converting enzyme. ECE-1 is the physiologically active ECE (18). It 
possesses two splice variants, ECE-1a and ECE-1b, which have functionally distinct 
roles and tissue distributions (19). ECE-1a is expressed in the Golgi apparatus of 
‘producer’ cells, such as endothelial cells, and appears to be responsible for 
intracellular processing of bigET-1 to ET-1 in such cells. ECE-1b is expressed in 
‘responder’ cells, such as vascular smooth muscle cells, and is transported to the plasma 
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membrane where it acts to cleave extracellular bigET-1. Two more isoforms, ECE-1c 
and ECE-1d have also been identified (20). A second form of ECE (ECE-2) has been 
cloned and characterized (21). ECE-2 is similar to ECE-1 in that it is membrane bound, 
inhibited by phosphoramidon and exhibits selectivity for bigET-1. However, ECE-2 is 
active only at acidic pH (5.5) and is not expressed on the cell's surface (21). Thus, 
ECE-2 could act as an intracellular enzyme responsible for the conversion of 
endogenously synthesized big ET-1 in acidic environments. ECE-1 and ECE-2 are 
relatively selective for big ET-1, having much less activity in cleaving big ET-2 and big 
ET-3. It is probable that there is other, as yet unidentified, ECE that are responsible for 
cleavage of ET-2 and ET-3. Both ECE-1 and ECE-2 are inhibited by phosphoramidon, 
but not by selective neutral endopeptidase and angiotensin converting enzyme (ACE) 
inhibitors (13)  
 
1-4 Plasma concentrations and clearance of ET-1 
In healthy subjects, circulating concentrations of ET-1 in venous plasma are in the range 
1–10 pmol/l (22;23). This concentration is lower than those which cause vascular 
contraction in vitro and in vivo, although concentrations at the interface between an 
endothelial cell and vascular smooth muscle are likely to be much higher. It has been 
reported that cultured endothelial cells secrete ET-1 into basolateral (abluminally) 
compartment and not in the apical (luminally) compartment (24). Thus, ET-1 appears to 
be primarily a locally acting paracrine substance rather than a circulating endocrine 
hormone. Venous plasma bigET-1 and the inactive C-terminal fragment of ET-1 
concentrations have been used as a marker for endothelial synthesis of the peptide and 
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reflect better the exact amount of ET-1 generated as compared to ET-1 concentration 
(25), because circulating ET-1 is rapidly eliminated from the circulation. Although 
clearance of ET-1 from the circulation is very rapid and its biological half-life is about 
one min its pressor effects are maintained for about one hour (26). ET degradation 
happens mainly locally by endopeptidases (neutral endopeptidase, NEP) and cathepsins 
G generated from endothelial (in vascular) and epithelial cells (in lung) (27;28). ET-1 
circulating is eliminated by kidney, liver and especially lungs which are responsible for 
50% of elimination of ET-1 in human (29). A second metabolic pathway of ET appears to 
be mediated through receptor binding and then internalization (28). Pulmonary clearance 
of labelled ET-1 can be blocked by pretreatment with a large dose of unlabelled ET-1, 
suggesting that clearance of ET-1 is receptor-dependent (26). Blockade of ET receptors 
of the ETB subtype, but not of the ETA subtype, increases plasma concentrations of ET-1 
and ET-3 (30) and prolongs the biological half life of exogenous [125I]-endothelin-1(31). 
This blockade increases circulating level of ET-1 within 15 min (30;32) without affecting 
bigET-1 and C-terminal fragments concentrations (25), confirming that this increase is 
mediated by displacement of ET-1 from receptors rather than through peptide synthesis. 
These reports also suggest that ETB receptors play an important role in ET-1 clearance. 
 
1-5 ET-1 receptors   
ET-1 exerts its biological actions through the activation of two receptor subtypes, ETA 
and ETB (33;34). Both ETA and ETB, receptors belong to a large family of 
transmembrane guanine nucleotide-binding protein-coupled receptors (GPCRs). They 
contain seven transmembrane domains of 22-26 hydrophobic amino acids in their 400-
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aminoacid sequences with an N-terminal extracellular region and C-terminal intracellular 
region (33-35). It is currently not clear whether receptors dimerization into homo-or 
heterodimers plays a role in ET-1 receptors activity and function in vivo (36). ETA 
receptors are highly expressed in VSMC but are also found in cardiomyocytes, 
fibroblasts, hepatocytes, adipocytes, osteoblasts and brain neurons (33;37) and exhibit 
higher affinities for ET-1 and ET-2 than for ET-3 (33). Potent peptide and non-peptide 
ETA antagonists have been synthesized, the prototype being the pentapeptide BQ-123 
(38). ETB receptors exist predominantly in endothelial cells and smooth muscle cells, but 
are also found in cardiomyocytes, hepatocytes, fibroblasts, osteoblasts, different types of 
epithelial cells and neurons and have equal subnanomolar affinities for all ET iso-
peptides (34). ET-1 binding to ETA and ETB receptors on smooth muscles produces 
vasoconstriction, cell growth and cell adhesion (39) (Fig.3). The binding of ET-1 to 
endothelial ETB receptors stimulates the release of nitric oxide and prostacyclin (Fig.3) 
which prevents apoptosis, inhibits ET converting enzyme-1 (ECE-1) expression in 
endothelial cells and plays an important role in ET-1 clearance (40;41). Several agonists 
selectively activate the ETB over the ETA receptors which include ET-3 (~2000-fold 
selectivity) and sarafotoxin S6c (~300 000-fold selectivity) (42). Up to date several 
selective and non-selective ET-1 receptors inhibitors have been discovered. For example, 
BQ-788 is a selective peptide antagonist of the ETB receptor (43). The majority of 
currently used ET agonists are shown in Table 2.  
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1-6 Biological actions of ET 
1-6-1 Action of ET in the vasculature 
In VSMCs, activation of ETA and ETB by ETs is responsible for persistent 
vasoconstrictor response, whereas stimulation of ETB, in the endothelium, causes a 
transient vasodilatation, which usually precedes vasoconstriction. The vasodilatation is 
attributed to the release of nitric oxide via activation of endothelial NO synthase. It has 
been reported that ET-1-induced PKB phosphorylation leads to phosphorylation and 
activation of NO synthase in endothelial cells (44). Prostacyclin production has been also 
involved in ETB-mediated vasodilatation (41). It has been suggested that NO release and 
vasodilatation are mediated by ETB1, whereas the subsequent vasoconstriction depends 
on ETB2 receptors (45). The ETs increase blood pressure in vivo in animals for at least 
one hour after a bolus dose (1) and in human, intravenous infusion of ET-1 increases 
blood pressure by 5–10% at doses of about one pmol/kg per min administered for over 
one hour (46). The coronary and renal vascular beds are most sensitive to the 
vasoconstrictor effects of systemic ET-1 (47). The mesenteric bed also constricts in 
response to systemic ET-1, whereas the hindquarter skeletal muscle bed exhibits only a 
little constriction (48). These differences among beds may be related to differences in 
constrictor (ETA and ETB) and dilator receptors (ETB) in these beds. The pressor effect of 
bolus doses of ET is usually preceded by transient hypotension that is most marked for 
ET-3 (49). When concentrations of ET-1 rise more slowly, hypotension does not occur 
(50). The hypotensive response to bolus administration of ET is used for demonstrating 
the endothelial actions of the ETs. 
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As a long-term effect in VSMC, ETs have been proven to evoke mitogenic activity and 
this effect seems to be mediated through ETA receptors activation (51;52). In addition to 
being a potent mitogen  for VSMC, ET-1 also potentiates the mitogenic effects of growth 
factors such as PDGF, EGF and basic fibroblast growth factor (bFGF)  and is considered 
as a co-mitogen with these growth factors (52). 
 
1-6-2 Action of ET in the heart 
The biological effect of ET-1 on cardiac tissue has been reported in several studies. ET 
has been found to exert a positive inotropic effect on human myocardium in vitro by 
activation of the sodium proton exchanger and increasing sensitization of cardiac 
myofilaments to Ca2+ (53). Recently, the activation of Na+/H+ exchange by ETs has been 
shown to be mediated by PKC (54). Na+/H+ exchange causing an increase in intracellular 
Na+ concentration and alkalinisation (37). While the former effect activates the Na+/Ca2+ 
exchange leading to an increase in intracellular Ca2+ concentration and myocardial 
contractility, the latter (alkalinisation) improves myofibrillar Ca2+ sensitivity (37). 
At the same time ET-1 evokes prolongation of the duration of the action potential (55). 
Thus, this pharmacological action of ET-1 may contribute to the pro-arrythmogenic 
property of the peptide when it is endogenously released or exogenously applied (56). 
Interestingly, in postmyocardial infarction of heart failure, ET-1 induces more positive 
inotropic response compared to healthy heart because of a high responsiveness to ET-1 in 
this pathological state (57). ETs also influence heart function indirectly by inducing 
vasoconstriction in coronary artery. Furthermore, it has been suggested that, during 
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exercise, ET-1 level was significantly increased in heart and ET-1 participates in the 
modulation of cardiac function during exercise in rats (58). 
 
1-6-3 Action of ET-1 in the nervous system  
An intracerebroventricular administration of ET in conscious rats, dose-dependently 
elevated blood pressure and also increased heart rate (59). These effects depend on ETA 
receptors activation and not ETB receptors (60). Many other laboratories have confirmed 
these results (61;62) which suggested a central pressor action of ET. On the other hand, 
Makino et al have shown that intracerebroventricular administration of ET increases 
plasma catecholamine levels suggesting that the central pressor action of ET might be 
mediated by catecholamine release to the periphery (63). In contrast, however, 
Yamamoto et al have reported that intracerebroventricular ET-1 stimulates vasopressin 
secretion leading to increased blood pressure with a reduction in renal water and 
electrolyte excretion (62). It has been also reported that ET via both sympathetic nervous 
system and hypothalamo-pituitary-adrenal axis, and through its interaction with brain 
natriuretic peptide (BNP) in the central nervous system may regulate cardiovascular and 
hormonal functions. (63).  
 
1-6-4 Action of ET in the Kidney 
 Many cells in the kidney produce ET-1 (64). Renal ET-1 and receptors localize 
predominantly in the medulla, and the production of ET-1 in this region exceeds that of 
anywhere else in the body (65). The contribution of ET-1 to regulation of renal function 
under normal physiological conditions has been studied by several groups. The effect of 
 
 16
ET-1 in the renal medulla is natriuretic, diuretic and hypotensive. Although, it is largely 
accepted that ET-1 action promotes sodium and water excretion thereby induce diuresis 
under physiological circumstances (66-68), other studies have suggested an attenuating 
role of ET-1 in urinary sodium excretion (69;70). Recently, by using transgenic mice 
exhibiting collecting duct-specific knockout of ET-1, data from Kohan et al have 
confirmed the fact that ET-1 promotes sodium and water excretion (71;72). Several 
potential mechanism by which ET-1 induces sodium and water excretion have been 
proposed, one of which involves ET-1-induced inhibition of tubular Na+/K+-ATPase 
activity in the proximal tubule and collecting duct (66). In addition, ET-1 has also shown 
to block reabsorption of water in the collecting duct by inhibiting the effects of anti-
diuretic hormone (ADH) on tubular osmotic permeability (67). The natriuretic and 
diuretic effects of ET-1 appear to occur via ETB receptor since the effects were 
specifically blocked only by ETB receptor agonists and not by ETB A receptor antagonist 
(73). In addition, it has been reported that ETBB receptor knockout mice have hypertension 
secondary to renal retention of sodium (19). 
Due to its potent vasoconstrictor action, ET-1 has been considered to be important in 
regulating renal vascular tone. ET-1 contracts afferent and efferent arterioles equally in 
vitro (74) and thus reduces both renal plasma flow and glomerular filtration rate (GFR) 
(75). Both ETA and ETB receptors participate in ET-1-mediated vasoconstriction of 
afferent arterioles (76).  
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1-6-5 Action of ET in the endocrine system 
ET-1 has also been shown to stimulate secretion of several hormones throughout the 
body. ET-1 stimulates both cortical and medullo adrenal hormones, it enhances the 
release of aldosterone from isolated cortical zona glomerulosa cells (77) and of 
adrenaline from medullary chromaffin cells (78). ET-1 stimulates production and release 
of atrial natriuretic peptide (ANP) by cultured atrial myocytes in vitro and in vivo 
(79;80). An inhibitory role of ET-1 on renin release from isolated rat glomeruli (81) and 
from rat juxtaglomerular cells (82) has also been reported. On other hand ET-1 has been 
reported to stimulate endothelial ACE activity (83). Taken together these findings show 
that ET-1 has contrasting effects on the renin–angiotensin system. ET-1 and ET-3 have 
also been found to be implicated in the release of testosterone by stimulating basal and 
gonadotrophin-induced testosterone production although the effects of ET-3 were less 
marked in rat Leydig cells (84). 
In adipose tissue, ET-1 inhibits adiponectin secretion through a phosphatidylinositol 4,5-
bisphosphate/actin-dependent mechanism (85). It has been reported that a decrease in 
adiponectin (secreted by white adipose tissues) expression and secretion have been 
positively correlated with a decrease in insulin sensitivity (85). More recently, by using 
RT-PCR and real-time PCR analyses, Chai et al have proposed another mechanism by 
which ET-1 evokes insulin resistance, they have demonstrated that ET-1 is able to 
increase IL-6 secretion from adipocytes which is a critical step for insulin resistance.(86). 
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1-7 Role of ET-1 in cardiovascular diseases  
Because of the ability of ET system to modulate a wide variety of cellular function it has 
been implicated in the pathophysiology of cardiovascular diseases such as, hypertension, 
atherosclerosis, coronary artery disease, heart failure as well as in diabetes, primary 
pulmonary hypertension, pulmonary fibrosis, scleroderma, renal failure, prostate cancer 
and its metastasis (87-90).  
 
1-7-1 ET-1 in hypertension  
1-7-1-1 ET-1 in experimental hypertension   
Significant increases in plasma ET-1 levels are consistently seen in only certain models 
of hypertension. Deoxycorticosterone acetate (DOCA) salt-hypertensive rats, Dahl salt-
sensitive rats, Ang II-induced hypertension, 1-kidney 1-clip Goldblatt hypertensive rats, 
and stroke-prone spontaneously hypertensive rats (SHRs) are among the models that 
exhibit an increase in systemic levels of ET-1 (91;92). As a consequence of the enhanced 
production of ET-1 in these models, ET-1 contributes to the remodeling of arteries in 
hypertension (93). Interestingly, the models of experimental hypertension that evoke 
increase in ET-1 systemic level also exhibit hypertrophic remodeling of resistance 
arteries with increased cross-sectional area, which is believed to be the results of the ET-
1 action (94), rather than the eutrophic remodeling without true vascular hypertrophy 
often found in essential hypertension and in spontaneously hypertensive rats (93).   
Flamant et al have suggested a critical role of EGF receptor transactivation in the 
vascular fibrotic response that is associated with ET-1-dependent vascular remodelling 
(95). It has also been reported that ET-1 stimulates DNA synthesis of VSMC which is an 
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index of proliferation and remodelling, via ETA receptor (52) and through transactivation 
of EGFR (96). Studies using vessels from male Wistar rats have revealed the mechanism 
by which ET-1 induces remodelling. These studies have suggested that ET-1- induced 
inward eutrophic remodelling seems to response to sustained contraction, which involves 
collagen reorganization through 3-integrins (97). It has been reported that ET-1 activates 
NADPH oxidase in VSMC and in blood vessels (98) and ET-1-induced proliferation may 
be mediated partly by increased ROS production (99). In aldosterone-induced 
hypertension systolic blood pressure, plasma ET-1, systemic oxidative stress, and 
vascular NADPH activity was increased. Enhancements of collagen, fibronectin and 
intercellular adhesion molecule (ICAM-1) have been shown to be associated with small 
artery hypertrophic remodeling in this hypertensive model (100). In the same study, BMS 
182874, an ETA receptor antagonism, attenuated vascular remodeling, fibrosis and 
oxidative stress as well as adhesion molecule expression in aldosterone-induced 
hypertension (100). Involvement of ET-1 in renal and cardiac target organ damage in 
hypertension has been documented. Studies have confirmed an implication of ET-1 in 
renal fibrosis through stimulation of growth factors and by inducing inflammation in 
hypertensive rats (101). In these studies an increase in renal ET-1 in hypertensive rats 
was shown to be associated with enhancements in transforming growth factor (TGF)-1, 
basic fibroblast growth factor (bFGF), procollagen I expression and matrix 
metalloproteinase (MMP)-2 activity. In addition, it was also demonstrated that a selective 
ETA antagonist was able to normalize these events. (101). Although, the role of ET-1 in 
promoting renal fibrosis has been confirmed, implication of ET-1 in renal damage 
associated with hypertension is still controversial. It has been demonstrated that in Ang 
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II-infused mice, the non-selective ET-1 receptor blocker, bosentan, prevented activation 
of the procollagen gene (102). By using the same blocker, Muller et al have shown a 
reduction in renal damage in rats overexpressing human angiotensinogen and human 
renin, that develop hypertension (103). On the other hand, Rothermund et al have 
suggested that ET-1 is not involved in renal damage and mortality in primary renin-
dependent hypertension (104). Recently, it has been demonstrated that a selective ETA 
receptor blockade not only reduces podocyte (cells of the visceral epithelium in the 
kidneys) injury and end-organ but also improves growth and survival independently of 
hypertension (105). In the heart, ETA (106) or combined ETA/ETB (103) or ECE inhibitor 
(107) blockade prevented target organ damage in hypertension animal models. Recently, 
Vanourkova et al gave evidence showning that blockade of the ET-1 system prevented 
the rise in cardiac ET-1 concentration in transgenic rats with inducible malignant 
hypertension. They suggested that ET-1 receptor blockade may provide evidence for ET 
blockade as a tool to protect rats from hypertensive cardiac damage (108). 
 
1-7-1-2 ET-1 in essential hypertension.   
Systemic concentration of ET-1 does not reflect the real production of ET-1 because ET 
is generated and acts locally. Studies investigating the role of ET in essential 
hypertension have revealed no change in plasma ET-1 concentration in hypertensive 
patients as compared with normotensive (4), whereas, plasma ET-1 level rises in African 
Americans hypertensive subjects (109). It has been shown that the increases of plasma 
ET concentration seem to be related to aging, smoking and renal dysfunction rather than 
essential hypertension (110). ETA receptor antagonists cause vasodilatation in forearm 
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vessels of both normotensive and essential hypertensive patients (111), and improve 
impaired vasodilation in hypertensive patients. On the other hand, the ETB antagonist 
induces vasoconstriction on forearm resistance arteries in normotensive subjects 
(112;113) and  had a vasodilator action on the forearm circulation of hypertensive 
subjects (113), indicating that a vasoconstrictor effect of ETB receptors could be found in 
hypertensive but not normotensive individuals. African Americans patients appear to 
have increased numbers of smooth muscle vasoconstrictor ETB receptors (109;114), 
which may explain the important role of the ET-1 system in these subjects. Both selective 
and dual-acting ET-1 receptor blockers can reduce systemic blood pressure in animal 
models and in hypertensive patients. Clinical studies recruiting 293 patients with mild-to-
moderate essential hypertension revealed that bosentan, an antagonist of both ETA and 
ETB receptors, was able to significant lower diastolic blood pressure in these patients. 
This reduction was similar to that observed with the ACE inhibitor enalapril (115). 
Furthermore, in animal experimentation, combination of ET-1 receptor antagonist, 
bosentan and ACE inhibitor leads to additional hypotensive effect in hypertensive dogs 
(116). The selective ETA antagonist darusentan reduced systolic blood pressure by 6.0 to 
11.3 mm Hg (117). Elevation of liver enzymes, a side-effect found with bosentan, was 
not encountered with darusentan in this study. Recently, safety and efficacy of darusentan 
have been evaluated in the treatment of hypertension and heart failure (118). Although, 
the effect of ECE inhibitor has not been studied in essential hypertension in human, 
encouraging results have been reported in SHR where phosphoramidon, an ECE 
inhibitor, lowered mean arterial pressure when infused in conscious SHRs (119). 
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Data from recent study shows that moderate aerobic exercise reduces ET-1-mediated 
vasoconstrictor tone. These reductions in ET-1 system activation may be the mechanism 
by which exercising contribute to the known beneficial affects to prevent or treat 
hypertension. (120). Finally, as mention above, aging is cardiovascular risk factor which 
exhibits increased ET-1 system activation which may be one cause of aging-promoted 
hypertension (121). 
1-7-2 ET-1 in atherosclerosis  
Endothelial cell injury, inflammation, monocyte infiltration of the vessel wall, cytokines 
and growth factors releases, migration of VSMC to the intima, and lipid accumulation in 
foam cells are the main characteristics of atherosclerosis (87). Evidence from several 
groups has suggested the involvement of ET-1 in development and progression of 
atherosclerosis (87;122). It has been documented that ET-1 is a chemoattractant for 
monocytes and macrophages and acts as a comitogen for VSMC (123;124). Lerman et al 
have shown a significant increase in plasma ET-1 concentration and this increase is 
correlated with the number of atherosclerotic lesions in atherosclerotic patients (125). 
Together with the fact that ET-1 has a short half-life in the circulation (126), these raised 
plasma levels are likely to be due to increased tissue ET-1 production. Upregulation of 
ET-1 and ET receptors have been demonstrated in atherosclerotic lesions in human and 
experimental animal models (127). Recently, another parameter of ET system which is 
ECE-1, has been shown to be significantly increased in apolipoprotein E-deficient (apoE) 
atherosclerotic mice (128). By studying ET-1 mRNA expression in normal and 
atherosclerotic human coronary arteries, Winkles et al. have suggested that endothelial 
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cells, monocyte-derived macrophages and VSMCs within the atherosclerotic lesion are 
capable of synthesising ET-1 (129). In the same regard, it has been reported by using 
cultured human VSMC from atherosclerotic coronary arteries that ET-1 production is 
markedly increased in coronary atherosclerotic plaques which may contribute to the 
development or progression of coronary artery disease (130). Both ETA and ETB 
receptors have been shown to be linked to atherosclerosis pathology. It has been 
demonstrated that both receptors are localized in endothelial cells, smooth muscle cells 
and macrophages in atherosclerotic plaques in hyperlipidemic hamsters (131). Moreover, 
chronic ETA receptor blockade normalized NO-mediated endothelial dysfunction and 
reduced atheroma formation in atherosclerotic apolipoprotein E-deficient mice (132). In 
human, infusion of the selective ETA receptor antagonist BQ123, improves coronary 
vascular function in patients with atherosclerosis. These data suggest that ET-1 receptor 
blockade may be a new therapeutic strategy to improve coronary vascular function in 
patients with atherosclerosis (122).  Additional mechanism by which ET-1 induces 
atherosclerosis has been revelled recently. Ballinger et al have demonstrated that ET-1, 
via ETA receptors, induces changes in the structure of glycosaminoglycan (GAG) that 
increases its binding to low density lipoprotein (LDL) and modifies its lipid binding 
proprieties within the vascular wall (133).  
Neointimal formation is the major cause of vessel occlusion observed following balloon 
angioplasty. Injury to the vascular endothelium and underlying tissue initiates intimal 
thickening with migration of medial VSMCs towards the intima where they change from 
the contractile to synthetic phenotype. The resultant thickened intimal layer forms a 
pronounced neointima, narrowing the vessel lumen and acting as pro-atherosclerosis 
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(134). ETA receptors have been identified on proliferating cells in the neointima of 
porcine vein grafts and balloon-injured porcine coronary arteries (135). Infusion of 
exogenous ET-1 has been shown to potentiate the development of intimal hyperplasia 
following balloon catheter injury (136) whilst mixed ETA/ETB receptor antagonists or 
ECE inhibitor reduced angioplasty-induced neointima formation (135;137;138) which 
further support a role of ET-1 system in this process.  
1-7-3 ET-1, Gi protein and hypertension 
Guanine nucleotide regulatory proteins (G proteins) are a family of GTP-binding proteins 
that play an important role in the regulation of a variety of signal transduction systems, 
including the adenylyl cyclase/cAMP system. The activity of adenylyl cyclase is 
regulated by two G proteins, Gs (stimulatory) and Gi (inhibitory). Alterations in the 
levels of Gi proteins and cAMP levels that result in the impaired cellular functions lead to 
various pathological states such as hypertension. Studies have been shown an increased 
expression of Gi proteins and Gi protein mRNA in hearts and aortas from spontaneously 
hypertensive rats (SHR) and in hearts from experimental hypertensive rats including 
deoxycorticosterone acetate (DOCA)-salt hypertensive rats and  1 kidney 1 clip (1K1C) 
rats with established hypertension with established hypertension (139-142). VSMC from 
SHR exhibited enhanced levels of Gi protein as compared to WKY rats, which were 
restored to control levels by antioxidants, suggesting a role of oxidative stress in this 
process. (143). ET-1 treatment has been shown to increase both Gi-2 and Gi-3 
expression without affecting Gs expression level in A10 VSMC (144) this may explain 
the mechanism by which ET-1 contribute to established hypertension. Similar to ET-1, 
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Ang II and arginine vaspressin have been also reported to increase the levels of Gi 
proteins in VSMC, whereas atrial natriuretric peptides (ANP) and nitric NO, which 
increase cGMP levels, decreased Gi protein expression in the cells (144-146). In this 
context, it seems that ET-1 and NO have opposite action on Gi expression and adenylyl 
cyclise activity which explains le vascular protection effect of NO as well as the 
mechanism by which ET-1 contribute to establish hypertension.     
1-7-4 ET-1 in heart failure  
Circulating ET-1 levels have been shown to be increased not only in animal model but 
also in humans with heart failure (147;148).  In addition, the degree of plasma levels of 
ET-1 correlates with the magnitude of alterations in cardiac hemodynamics and 
functional class (149). It seems that low cardiac output, observed in heart failure, serves 
as a stimulus for endot release because very high levels have been documented in animals 
with low cardiac output and low ventricular filling pressures produced by thoracic 
inferior vena cava constriction (150). Both selective (ETA receptor) and non-selective 
(ETA/ETB receptors) ET receptor inhibitor have been shown to be beneficial in limiting 
heart failure complication. Indeed, oral ET-receptor antagonist, bosentan, improved 
systemic and pulmonary hemodynamics in heart failure patients. (151), same results have 
been seen with a selective ETA receptor inhibitor (152). In fact a selective ETA receptor 
blockade improved cardiac index in patients with congestive heart failure (152). Ohnishi 
et al compared the effects of selective ETA and mixed ET A/B receptor antagonism using 
FR139317 and TAK-044, respectively, in conscious dogs with heart failure. Both agents 
improved cardiac function in these studies (153). Recently, by using anesthetized rats, 
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Rufanova et al have shown that myocardial contractility was restored and cardiac 
relaxation significantly improved after the application of  PP36 an inhibitor of ECE 
application suggesting a crucial role of ET production in this pathophysiology state (154). 
 
1-8 ET-1induced signaling in vascular smooth muscle cells 
ET-1 exerts its physiological actions through the activation of multiple signaling 
pathways which include the PLC/DAG/IP3, MAPKs, and PI3-K/PKB pathways. As 
shown in Fig. 4 and 8, many receptor and non-receptor tyrosine kinases also play a role in 
initiating the ET-1-induced signaling events. The cellular events triggered by the 
activation of these signalling pathways play important role in regulating the cellular 
growth, proliferation, contraction and survival of VSMC, and aberration in this pathways 
results in the pathological states. 
 
1-8-1 ET-1-induced activation of phoshoinositide cascade  
The binding of ET-1 to its receptor activates heterotrimeric guanine nucleotide binding 
(G) proteins such as Gq which is the best characterized signal transducer for ETA 
receptor. As with all heterotrimeric G-proteins, Gq consists of an -subunit (q, or 
related -subunit, such as 11), a member of the -subunit family as well as a member 
of the -subunit family and is associated with the membrane (35;155). In the inactive 
Gq heterotrimer, q is ligated to guanosine diphosphate (GDP) and exchange of GDP 
for guanosine triphosphate (GTP) on q leads to the dissociation of q(GTP) and   
and both remain associated with the membrane (35). Their dissociation leads to the 
activation of phosphoinositide-specific phospholipase C (PLC ) (156;157), which 
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then hydrolyzes the membrane phospholipid, phosphatidylinositol-4’,5’-bisphosphate 
[PtdIns(4,5)P2] to generate two second messengers: hydrophobic diacylglycerol (DAG), 
which remains in the membrane, and soluble inositol-1’,4’,5’-trisphosphate 
[Ins(1,4,5)P3] (156;157). Ins(1,4,5)P3 diffuses into the cytoplasm and activates calcium 
channels of the sarcoplasmic reticulum, which leads to an increase in Ca2+ levels in the 
sarcoplasm and cell contraction. DAG together with Ca2+ activates the 
phosphatidylserine-dependent protein kinase, protein kinase C (PKC) (Fig.4). The PKC 
family of serine/threonine kinases have been subdivided into three groups: the classical 
or conventional PKCs, which require DAG and Ca2+, include the isoenzymes and  
(158), the novel PKC (nPKC) which are DAG-dependent, but Ca2+-independent, 
include the isoenzymes  	
 and   (158;159) and the atypical PKC (aPKC), 
which are independent of DAG and Ca2+ and include  and  isoenzymes (158;160). 
ET-1 has been shown to activate PKC in cardiomyocytes (161) and in other cells 
(162;163). Many studies have implicated PKC in the deleterious vascular effects of a 
variety of pathologies including diabetes and hypertension (164). PKC has been shown 
to be involved in ET-1-induced signalling in VSMCs (165;166). Moreover, growing 
evidence suggests that PKC activity modulates proliferation (166;167) and contraction 
of VSMCs evoked by ET-1 (168). Recntly, by using human VSMC, Chen et al have 
reported an implication of PKC in ET-1-induced ERK activation through ETA receptors 
(169). Thus, ET-1-induced activation of PKC and its downstream effects appear to be 
important in regulating vascular functions.  
In addition to PLC via Gq, ETA and ETB receptor subtypes are functionally coupled to 
adenylate cyclase, via Gs in VSMC and Gi in endothelial cells respectively. (170;171). It 
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has been also reported in other cell types that the calcium signal induced by ET-1 is 
consequent to both an activation of PLC and inhibition of the calcium pump, both 
effectors being coupled to the ETB receptor by different G proteins, Gq and Gs, 
respectively (172). 
1-8-2 Calcium calmodulin system in ET-1 signaling  
It has been shown that, in VSMC, ET-1 evokes increase in intracellular calcium 
concentration via a stimulated plasma membrane Ca2+ entry and/or sarcoplasmic 
reticulum Ca2+ release (173-175). Cytoplasmic Ca2+ is tightly controlled and in the 
unstimulated state it is believed to be around 100 nM.  In response to various signalings 
this concentration can rise up to 300-500 nM this increased Ca2+ signals participates in 
many cellular functions including short-term contractile, secretory, or metabolic 
responses to longer term regulation of transcription, growth, and cell division (176). 
Through the activation of PLC, ET-1 generates the second messengers IP3 and DAG. 
IP3 diffuses rapidly within the cytosol and interacts with IP3 receptors (IP3R) located on 
the endoplasmic reticulum, which function as calcium channels to release calcium stored 
in the endoplasmic reticulum lumen and generate the initial calcium signal phase as 
mention in the previously section. The resulting depletion of calcium stored within the 
endoplasmic reticulum lumen functions as the primary trigger for a message that is 
returned to the plasma membrane. The lowered luminal Ca2+  causes dissociation of Ca2+  
bound to the low-affinity EF-hand Ca2+ -binding site on the N-terminus of stromal-
interacting molecule (STIM)1, which is considered as a ‘‘sensor’’ of Ca2+ within ER Ca2+  
store (177). This Ca2+ dissociation causes STIM1 molecules to aggregate and be 
translocated close to the plasma membrane (177). At this level STIM1 interacts directly 
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with Orai1 protein, (178) which serve as highly Ca2+-selective store-operated channel 
(179) and allow entry of external calcium. This sustained calcium entry phase mediates 
longer term cytosolic calcium signals and provides a means to replenish intracellular 
stores (180).  
The other product of PLC activation, DAG, also has important effects on calcium entry 
channels. Transient receptor potential channels (TRPC) have been reported to play a 
major role in GPCR-induced Ca2+ entry in VSMC and other cell types (180;181). DAG 
has been shown to triggers Na+ entry via TRPC6 activation (178;182) which in turn 
induces membrane depolarization resulting in  activation of Ca2+ entry through L-type 
voltage-activated Ca2+ channels (178).The TRPC6 channels also appear to be activated 
by mechanical stretch, resulting again in depolarization and L-type Ca2+ channel 
activation (183). 
An important effector of Ca2+ is calmodulin (CaM) and many diverse actions of Ca 2+ and 
CaM signaling are known to be mediated through Ca2+/CaM-dependent protein kinases 
(CaMK). CaMKs are serine/threonine kinases that are regulated by Ca2+ liganded CaM. 
Myosin light chain kinase (MLCK) and phosphorylase kinase are Ca2+/CaM-dependent 
protein kinases which are dedicated to a particular substrate. Elongation factor-2 (EF-2) 
kinase (originally termed CaMKIII) is also a kinase dedicated to the phosphorylation of a 
single substrate (184). In contrast, CaMKs are multifunctional CaMKs (185) some 
member of this family e.g. CaMKI, II and IV exhibit a board substrate specificity 
whereas others members are more selective. In the context of cardiovascular system, 
CaMKII has generated a lot of interest because of its potential involvement in myocardial 
physiology and diseases (186) 
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Fig.4: Activation of MAPK pathway by ET-1 in VSMC. ET-1 receptor stimulation 
leads to G-protein b activation which activates PLC . Activated PLC  converts PIP2 
to IP3 and diacylglycerol (DAG). IP3 elevates the concentration of intracellular calcium 
and participates in muscle contraction. DAG activates PKC. PKC and/or 
Ca2+/Calmodulin (CaM)-dependant protein kinase (CaMK) activate receptor and non-
receptor tyrosine kinases. Activation of these components signals the stimulation of 
Ras/Raf/ MEK /ERK1/2, p38 mapk and JNK. The MAPK family members are 
translocated to nucleus and regulate nuclear events by activating transcription factors 
through phosphorylation. 
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1-8-2-1 CaMKII  
There are four known isoforms of CaMKII (, , , ) which are encoded by separate 
genes.  and -CaMKII are the predominant neuronal isoforms and the and  isoforms 
are expressed in diverse tissues including the heart (187). In heart, the predominant 
isoform is (188) whereas both  and isoforms have been shown to be express in 
VSMC (189;190). 
1-8-2-1-1 Structure of CaMKII 
Monomeric structure
The CaMKII monomer consists of an NH2-terminal catalytic domain, a centrally located 
regulatory domain, and a COOH-terminal association domain (Fig.5). The catalytic 
domain is needed to catalyze the transfer of the phosphate from ATP to serine or 
threonines embedded within a CaMKII consensus motif (191). The regulatory domain 
contains a pseudosubstrate sequence that, under basal conditions, binds and constrains the 
catalytic domain. A CaM binding domain is located in the regulatory domain. The 
pseudosubstrate sequence is found around an activating "autophosphorylation" site at 
Thr286 for isoform (Thr287 for ) (192) and a recently identified activating oxidation 
site (Met281/Met282) (193). Phosphorylation of Thr286 or oxidation of Met281 and Met282 
prevents the re-association of the catalytic and regulatory domains even after dissociation 
of Ca2+/CaM complex, thereby enhancing the CaMKII signal. An inhibitory 
autophosphorylation site, Thr 306/307, reacts with the Ca2+-CaM binding sequence. Basal 
phosphorylation occurs preferentially at Thr306, preventing Ca2+/CaM binding, resulting 
in decreased CaMKII activity (194). The association domain is responsible for the 
assembly of CaMKII monomers into the holoenzyme.  
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Holoenzyme structure  
The partial structure of the CaMKII holoenzyme has been determined by 
crystallographical studies. These studies have revealed that the ~600 kDa holoenzyme 
consists of two central rings stacked on top of each other, with a diameter of ~145 Å, 
formed by interaction of multiple association domains. This central ring serves as the 
scaffold from which an outer ring, consisting of the regulatory and catalytic domains, 
 
 
Fig.5 Linear diagram of a prototypical CaMKII subunit. The catalytic domain is 
autoinhibeted by pseudosubstrate autoregultory sequence that is disinhibited following 
Ca2+/CaM binding. The association domain produces the native form of the enzyme, a 
multimeric holoenzyme composed of 12 subunits. Isoform differences present in 
theand  isoforms of CaMKII are contributed primarily by a region of multiple 
alternatively  spliced sequences, termed variable insert, which reside in the association 
domain. Conserved site of autophosphorylation are indicated in autoregulatory domain.  
From (Hudmon and Schulman Biochem. J.  364: 593-611, 2002)  
 
 
arises (195). The holoenzyme is either a dodecameric (196;197) or a tetradecameric (195) 
structure. This arrangement allows for a high concentration of catalytic domains that can 
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interact with target proteins, including adjacent CaMKII monomers within the 
holoenzyme. CaMKII autophosphorylation (at Thr286 for  or Thr287 for ) critically 
depends on the arrangement of monomers within the holoenzyme. In vitro studies 
revealed that the holoenzyme structure is critical for autophosphorylation graded activity 
responses related to the frequency and duration of intracellular Ca2+ transients (198).  
1-8-2-1-2 Activation of CaMKII 
CaMKII requires Ca2+/CaM for activation (Fig.6). CaM is a bi-lobed intracellular protein 
that contains four Ca2+-binding EF hands (2 EF hands in each lobe). Under basal 
conditions, CaMKII is inactive because of intramolecular binding of the catalytic domain 
to the regulatory domain. However, a fraction of CaMKII is active even under this 
condition, because autophosphorylated Thr286/287 is detectable even in quiescent cells 
(199). This inhibitory interaction between the catalytic and regulatory domains prevents 
substrate and ATP binding (200-202). Calcified CaM (CaM and Ca2+ complex) binds to 
the regulatory domain, inducing a conformational change that frees the catalytic domain 
from its pseudosubtrate (203). The allosteric rearrangement of CaMKII  upon binding 
with Ca2+/CaM allows access to the ATP binding pocket, which in turn allows CaMKII to 
catalyze the transfer of a phosphate donor group to downstream targets, including its 
autophosphorylation. Autophosphorylation, which occurs by an intra-holoenzyme 
reaction (204), has several important implications for CaMKII activity. First, Thr286/287 
autophosphorylation results in a 1,000-fold increase in the affinity for binding with CaM, 
a property known as "CaM  
 
 34
 
Fig.6 CaMKII undergoes multiple autoregulatory states that may have an impact on its 
function following       Ca2+/CaM activation      From (Houdmon and Schulman Biochem.
J. 364, 593-611, 2002)  
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trapping" (205). Second, autophosphorylation results in the ability of the kinase to 
maintain catalytic activity even in the absence of CaM binding (192). Under resting 
conditions, phosphorylation occurs preferentially at Thr306, preventing Ca2+/CaM binding, 
which in turn results in decreased CaMKII activity.  
 
1-8-2-1-3 Role of CaMKII in heart diseases  
There is a growing evidence for a pathophysiological role of CaMKII in cardiac 
hypertrophy and heart failure for review, see reference (206). ET-1 has been shown to 
increase the activity of CaMKII and induces hypertrophy in cardiomyocyte. Pretreatment 
with KN-62, a CaMK inhibitor, was able to suppress ET-1-induced cardiomyocyte 
hypertrophy measured by -myosin heavy chain promoter activation and [3H] 
phenylalanine uptake (207). Hypertrophic responses induces by Leukemia inhibitory 
factor (LIF), a glycoprotein cytokine, was also attenuated by CaMKII inhibitor in 
cardiomyocytes (208). Furthermore, an increase in CaMKII expression (209) and activity 
(210) has been reported in hypertrophied myocardium from spontaneously hypertensive 
rat (SHR).  More recently, by using hearts extracted from CaMKIInull mice, a critical 
role of CaMKII in pathological cardiac hypertrophy and remodeling has been reported 
(211). CaMKII upregulation and activation has been found to play a role in development 
and maintenance of heart failure (208). Further evidence linking CaMKII and heart 
failure comes from studies suggesting that mice with genetic CaMKII inhibition reverse 
heart failure-associated changes (212). The mechanism by which CaMKII induces its 
cardiac alteration seems to be modulation of ryanodine receptor thereby regulating the 
Ca2+ leak from sarcoplasmic reticulum (213). CaMKII activation plays a role not only in 
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heart failure and cardiac hypertrophy but also in cardiac arrtythmias. It has been reported 
that CaMKII is a proarrhythmic signaling molecule in cardiac hypertrophy in vivo. (214) 
and calmodulin kinase inhibition prevents development of the arrhythmogenic transient 
inward current. (215). 
 
1-8-2-1-4 Role of CaMKII in vascular diseases  
Similar to the cardiac system, an involvement of CaMKII in regulating vascular function 
has also been suggested. It has been shown that CaMKII regulates proliferation of VSMC 
in thoracic aorta, (216) and in rat carotid arteries (217). Others studies indicated 
involvement of CaMKII in cell migration. siRNA-mediated suppression of CaMKII2 
resulted in the inhibition of wound-induced Golgi reorganization and ERK1/2 activation 
leading to cell migration (218) and insulin-stimulated cGMP inhibits VSMC migration by 
inhibiting CaMKII (219). In addition, by using an antisense knockdown of CaMKII 
gamma, it has been reported that CaMKII is essential for ERK-mediated signaling in 
differentiated smooth muscle cells (220). This notion is further supported by studies 
showing that pharmacological blockade of CaMKII by KN-93 improved vascular 
hyperplasia and hypertension in AngII-induced hypertensive rats (221), and normalized 
aberrant vascular reactivity in diabetes-induced vascular dysfunction (222;223). 
Furthermore, norepinephrine and Ang II-induced arachidonic acid release, which is 
considered as the first step of inflammation, have been shown to be mediated by 
CaMKIIactivation in rabbit aortic smooth muscle cells (189;224). More recently, 
CaMKII has been also found to be induced in smooth muscle cells during the response of 
an artery to injury and is a positive regulator of proliferation and migration in the vessel 
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wall contributing to neointima formation and vascular remodeling (217). Since a 
hightened proliferation and migration of VSMC are hallmarks of vascular disease, 
CaMKII has been suggested to play an important role in the pathogenesis of vascular 
diseases (221;222). 
 
1-8-3 ET-1-induced activation of MAPK cascade in VSMC 
ET-1 receptor activation also leads to the stimulation of MAP Kinase cascade (Fig.4). 
The first component of this cascade is Ras, a member of the small GTP-binding protein 
family. Ras cycles between an active GTP-bound conformation and an inactive GDP 
bound form (225). Once activated, Ras, bound to membrane, recruits Raf, also known 
as mitogen activated protein kinase kinase kinase MAPKKK (226). Raf phosphorylates 
MEK or MAPKK at specific serine/threonine residues, which in turn, phosphorylates 
MAPKs, such as extracellular signal regulated kinases 1 and 2 (ERK1/2) on threonine 
and tyrosine residues (227). MAPKs are serine/threonine protein kinases, which are 
activated in response to a variety of external stimuli such as growth factors, hormones 
and stress (228-233). Several reports have demonstrated that ET-1 activates ERK1/2 
signaling pathway in many cell types including cardiomyocytes (6), fibroblasts (234), 
glomerular mesangial cells (235) and VSMCs (10). ERK1/2, p38mapk and c-Jun N-
terminal kinases (JNK) are the principal MAPKs (236;237). MEK1/2 phosphorylate 
ERK1/2, which promote growth signaling, whereas, MEK 4/7 and MEK 3/6 
phosphorylate JNK and p38mapk respectively, which control survival, differentiation and 
inflammation (41;230;237;238). Several studies have suggested that the activation of 
MAPKs in response to ET-1 was responsible to promote proliferation in VSMC 
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(10;239). It has been demonstrated that ERK5, a new member of the MAPK family, 
which is involved in cell differentiation and cell cycle, is activated by ET-1 and 
angiotensin II , another vasoactive peptide with similar effects as ET-1, in VSMCs 
(240). A role of MAPKs activation in regulating the contraction of VSMCs in response 
to ET-1 and angiotensin II has also been reported (241-243).  
Activation of ERK1/2 leads to the phosphorylation of downstream cytosolic regulatory 
proteins, such as p90rsk which phosphorylates ribosomal proteins and participates in 
protein synthesis (244). Also, ERK1/2 and other MAPK family members are 
translocated from the cytosol to the nucleus (237;245) and phosphorylate many 
transcription factors which lead to activation of genes involved in growth and 
differentiation (237;246)(Fig.4). ET-1 also activates (but to a lesser degree than ERKs) 
JNK and p38mapk cascades in cardiomyocytes (6;247), in VSMC (248) as well as in 
mesangial cells (8). In addition to Ras, several other small G-protein families such as 
Rho, Rab and Ran have been shown to be stimulated by ET-1 (225). ET-1 activates 
members of the Rho family in cardiomyocytes (249) and fibroblasts (250), which are 
positive regulators of p38mapk pathway (251). The precise events that mediate ET-1 
induced activation of Ras/Raf/MEK and ERK1/2 remain poorly characterized, 
however, there is some evidence supporting the involvement of PKC in Ras activation 
in many cell types including cardiomyocytes (161) and rat myometrial cells (162). A 
possible role of a calcium-regulated cytoplasmic proline-rich tyrosine kinase 2, Pyk2 
(also known as related adhesion focal tyrosine kinase (RAFTK), focal adhesion kinase-
2 (FAK-2) and cell adhesion kinase  (CAK ), calcium-dependent tyrosine kinase 
(CADTK)), in the activation of MAPK has been suggested in primary astrocytes 
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(252;253) and rat kidney mesangial cells (254). Pyk2 is also activated by ET-1 in 
VSMCs and may serve as an upstream regulator of MAPK cascade in VSMCs (10). In 
several other cell types, Ca2+- and PKC-dependent Pyk2 activation (255) has been 
shown to link GPCRs to upstream regulators of MAPK-signaling, such as Src, Shc, 
Grb2, son of the sevenless (SOS) and the Ras guanosine nucleotide exchange factor 
(254;256;257).. Previous data has shown that ET-1-induced association of Pyk2 
through the binding of its autophosphorylated Tyr-402 to the SH2 (Src-homology 2) 
domain of c-Src leads to c-Src activation in many cell types including mesangial cells 
(254;256) and cardiomyocytes (258). Activated c-Src bound to Pyk2 might directly 
phosphorylate adjacent cellular proteins, such as p130Cas, which then act as docking 
protein to recruit its effectors able to activate JNK (259;260) in cardiomyocytes (247). 
Other studies have suggested that CaMKII may serve as an upstream regulator of 
MAPK pathway in VSMCs through the activation of Pyk2 (261), however a role of 
CaMKII in ET-1 evoked ERK1/2 activation is not Known. 
 
1-8-4 ET-1-induced PI3-K activation in VSMC. 
Phosphatidylinositol-3 kinases (PI3-Ks), which are a family of both protein and lipid 
kinases have also emerged as an important effector of ET-1 action. PI3-K catalyzes the 
transfer of phosphate from ATP to the 3’position of the inositol ring of the membrane-
localized phosphoinositides such as phosphatidylinositol (PtdIns), phosphatidylinositol-4-
phosphate (PtdIns-4-P) and phosphatidylinositol-4,5-bisphosphate (PtdIns-4,5-P2) and 
generates PtdIns-3-P, PtdIns-3,4-P2 and PtdIns-3,4,5-P3 respectively (Fig.7). These 
phospholipids act as second messengers to activate several proteins kinase such as  
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Fig. 7 Major pathways of phosphoinositol metabolism. (A) Structure of 
phosphoinositol (PtdIns) which is phosphorylated on the myoinositol head group to 
produce different phosphoinositides  (B) Metabolic pathways involved in PtdIns 
metabolism and the key role of lipid kinases and phosphatases. IP3, inositol 1,4,5-
triphosphate; DAG, diacylglycerol. Solid lines refer to well-established pathways.  
From  (Oudit GY et al PJ Mol Cell Cardiol. 37:449-71, 2004).  
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PtdIns-3,4,5-P3 dependent protein kinase (PDK), protein kinase B ( PKB)/Akt and 70 
KDa ribosomal protein S6 kinase  (p70S6K )(262). 
PI3-Ks are divided into three classes based on their structure and mechanism of 
regulation (262). Class I PI3-Ks generate PtdIns-3-P, PtdIns-3,4-P2,  PtdIns-3,4,5-P3 and 
are activated by receptor tyrosine kinases and G-protein-coupled receptors (263). Class II 
PI3-Ks generate PtdIns-3-P and PtdIns-3,4-P2 and possess a lipid binding domain, 
whereas, Class III PI3-Ks generate PtdIns-3-P only (263). Class I PI3-Ks are ubiquitously 
expressed and represent the dominant form in cardiovascular tissues (264)(Fig.7). Class I 
PI3-Ks are subdivided further into class IA and IB, and are heterodimeric proteins 
consisting of a catalytic and a regulatory (accessory) subunit. The catalytic subunits of 
class IA- PI3-K exist in three isoforms: p110 p110 and p110, among these, p110 
has more ubiquitous distribution than p110 and p110. Similarly, the regulatory adaptor 
subunit for classIA-PI3-K also has several isoforms: p85 ,p85 and p55 which are 
products of three genes and their splice variants (237). The class IA PI3-Ks are believed 
to be typically activated in response to tyrosine kinase coupled stimuli. In contrast to 
class IA PI3-K, the class IB enzyme (PI3-K) consist of a catalytic subunit PI3-K (p110) 
and a regulatory subunit (p101) and are usually activated by G  subunits of G proteins 
liberated by GPCR activation (264).  
 Except for rat glomerular mesangial cells where ET-1 was shown to directly increase the 
catalytic activity of PI3-K (161), a direct activation of PI3-K in VSMC has not been 
documented. However, an involvement of PI3-K as an upstream mediator of several ET-1 
induced responses has been reported. For example, a role of PI3-K in ET-1-induced Ca 2+ 
influx in carotid artery and in basilar artery contraction was recently shown by using 
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wortmannin and LY 294002 specific inhibitor of PI3-K (265;266). In mesangial cells, 
ET-1 receptor activation has been shown to stimulate PI3-K phosphorylation through Ras 
(257). Also, in rabbit internal carotid artery VSMCs, PI3-K appeared to be involved in 
ET-1-induced Pyk2 tyrosine phosphorylation (265). Conversely, studies using 
angiotensin (Ang II), a vasoactive peptide with similar effects to ET-1, have suggested 
that Pyk2 regulates PI3-K cascade specifically via interaction of Pyk2 with p130Cas 
which lead to their association with PI3-K in VSMC (49). Moreover, the recent work 
demonstrating that mice lacking PI3-K are protected from angiotensin-evoked smooth 
muscle contraction and hypertension provides further support for an important role of 
PI3-K signalling in vascular pathobiology (267).  
 
1-8-5 ET-1-induced PKB activation in VSMC. 
Several downstream targets of PI3-K have been identified. However, the most widely 
studied target is PKB, also known as Akt (a product of akt proto-oncogene). PKB is a 
serine/threonine kinase with three identified isoforms in mammalian system: 
PKB/Akt1, PKB/Akt2 and PKB/Akt3 (268-270). They are activated by dual 
phosphorylation on threonine and serine residues (Thr308 and Ser473 for PKB, Thr309 
and Ser474 for PKBand finely Thr302 and Ser472) for PKB (271) and contain a central 
catalytic kinase domain with specificity for serine or threonine residues in substrate 
proteins (271). N-terminal of PKB possesses a pleckstrin homology (PH) domain that 
binds phospholipids generated by PI3-K activation. A short glycine-rich region that 
bridges the PH domain to the catalytic domain follows the PH domain. The C-terminus 
of PKB is hydrophobic and possesses a proline-rich domain (272). 
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The lipid products of PI3-K bind with high affinity and specificity to the PH-domain of 
PKB with a preference of PtdIns-3,4-P2 over PtdIns-3,4,5-P3 (273). This binding 
induces translocation of PKB to the plasma membrane where its phosphorylation on 
Thr308 by  PDK-1 and Ser473 by a hypothetical kinase termed as PDK-2 is required 
for its complete activation (273) (Fig. 8).  
ET-1 has been shown to increase PKB activation in cardiomyocytes (274), in 
myofibroblast (275), in human umbilical vein endothelial cells (276) and in human 
osteoarthritis chondrocytes as well as in A-10 VSMCs (10). An involvement of PKB in 
vascular disease was suggested from studies in which an enhanced PKB activity was 
associated with angiotensin-induced hypertension in New Zealand White rats (277). 
Furthermore, a role of PKB in regulating the ploidy levels and hypertrophy of VSMCs 
has also been suggested in a model of hypertension (278). Several different substrates 
of PKB have been identified which include members of the cell survival/apoptosis 
cascade such as Bcl2 associated death promoter (BAD) (272;279), caspase (280) and 
glycogen synthase kinase 3 (GSK-3) (281), as well as key regulators of protein 
synthesis and cell growth such as mammalian target of rapamycin mTOR (282) (Fig.8). 
Thus, the stimulation of PI3-K/PKB signalling in response to ET-1 receptor activation 
has implications in regulating not only survival and death but also hypertrophic 
responses in VSMCs.  
 
1-8-6 ET-1-induced growth factor receptor transactivation 
There is an increasing body of evidence to suggest that vasoactive peptides such as ET-1 
whose receptor belong to GPCR family stimulate intracellular signalling pathway through  
 
 44
 
 
Fig.8: Activatin of  PI-3K/Akt pathway by ET-1 in VSMC. ET-1 receptor stimulation 
leads to G-protein b activation which activates PLC. Activated PLC converts PIP2 to 
IP3 and diacylglycerol (DAG). IP3 elevates the concentration of intracellular calcium and 
participates in muscle contraction. DAG activates PKC. PKC and/or Ca2+/Calmodulin 
(CaM)-dependant protein kinase (CaMK) activate receptor and non-receptor tyrosine 
kinases such as Src and Pyk2. Activation of these components can eventually contribute 
to the activation of PI3-K. PI3K activation leads to the production of PI(3,4,5)P3 from PI 
(4,5) which results in recruitment and activation of PKB. PKB has several effectors. 
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transactivation of receptor protein tyrosine kinases (R-PTK) (283). Among the various R-
PTK, the role of EGF-R, IGF-R and PDGF-R in this process has been investigated in 
some detail(284;285). 
 
1-8-6-1 Role of EGF-R 
The EGF-R is a R-PTK that is ubiquitously expressed in a variety of cell types, with the 
most abundant expression in epithelial cells and many cancer cells (286-288). It contains 
an extracellular ligand binding domain, a single transmembrane domain and a 
cytoplasmic tyrosine kinase autophosphorylation and regulatory domain (reviewed in 
(289)). EGF-R undergoes dimerization to induce autophosphorylation of tyrosine 
residues in its tyrosine kinase domain in response to ligand binding (287;290). 
Dimerization activates the intrinsic PTK activity of the intracellular domain leading to the 
phosphorylation of several key tyrosine residues. Phosphorylated tyrosines serve as 
docking sites for binding with Src homology 2 (SH-2) domain containing signaling 
proteins which trigger downstream events. The phosphorylation of EGF-R on Tyr1068 
recruits of the adaptor protein Grb2, leading to the activation of Ras/ERK1/2 pathway. 
 ET-1 has been shown to transactivate EGF-R by tyrosine phosphorylation in many cell 
types (96;258;291), and a critical role of this transactivation  in mediating ET-1-induced 
ERK1/2 activation has been suggested (96).  An increase in EGF-R phosphorylation and 
ERK1/2 activation was also reported in freshly isolated rat aorta in response to ET-1 
stimulation, and PD153035, an EGF-R PTK inhibitor, blocked ERK1/2 phosphorylation 
in these studies (258). An involvement of ET-1-induced EGF-R transactivation has been 
implicated in protein and DNA synthesis and c-Fox gene transcription in VSMCs 
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(96;292). In contrast  to the results of Iwasaki et al showing that ET-1-induced protein 
synthesis could be blocked by AG1478, an other blocker of EGF-R  , in vivo studies have 
failed to show any inhibitory effect of this inhibitor on total protein synthesis is small 
mesenteric arteries (293). However, these investigators did not examine the effect of 
AG1478 on EGF-R phosphorylation. A requirement of EGF-R transactivation in ET-1-
induced vascular contraction has also been shown in rabbit basilary artery rings (294) and 
in mouse aortic ring segments (95). Chansel et al reported that the ET-1-induced 
vasoconstriction in carotid artery segments in mice dependent also on EGF-R 
transactivation (291). This contractile response was dependent on ERK1/2 activation 
because pharmacological blockade of this pathway inhibited ET-1-induced contraction in 
basilary artery rings (294). Although, several studies in VSMCs  have suggested an 
involvement of ETA receptor in ET-1-induced EGF-R transactivation, recently , by using 
either the full-length ETB receptor or a N-terminally truncated,  a role of ETB receptor in 
this process has also been suggested (295). It thus appears that EGF-R transactivation 
plays a role not only in growth promoting /hypertrophic responses of ET-1, but also in 
mediating the contractile events induced by these two vasoactive peptides.  
 
1-8-6-2 Role of IGF-1R 
The IGF-1R is also a R-PTK that shares structural and functional homology with the 
insulin receptor. The mature receptor is a tetramer consisting of 2 extracellular -chains 
and 2 intracellular -chains (296). The -chains include an intracellular tyrosine kinase 
domain that is believed to be essential for most of the receptor’s biologic effects (297). 
Binding of IGF-1 or Insulin (at very high concentrations) induces the activation of PTK 
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domain of IGF-1R subunit which in turn activates the autophosphorylation of the 
receptor (reviewed in (298)). One of the earliest steps in signal transduction initiated by 
the IGF-1R is the phosphorylation of adaptor/docking proteins such as insulin receptor 
substrate (IRS-1 or IRS-2) and Shc (299;300). IRS-1, an important substrate for both the 
insulin and the IGF-1 receptor, contains multiple tyrosine phosphorylation sites that 
recognize and bind to SH2-domain containing signaling molecules, such as Grb2, Nck, 
the p85 subunit of PI3-K and the SH2 domain-containing tyrosine phosphatase-2 (SHP-2) 
(299). Of these, the binding of Grb2/Sos to tyrosine-phosphorylated IRS-1 activates Ras, 
which then stimulates the Raf-1/MAPK cascade (301). Shc can also interact directly with 
IGF-1R (302). After tyrosine phosphorylation of Shc, it recruits the Grb2/Sos complex 
and activates the Ras/Raf-1/MEK/ERK pathway (301). The activated IGF-1R also 
triggers the activation of PI3-K and its downstream targets PKB and p70s6k (303;304).  
It has been shown that ET-1 transactivates IGF-1R via Src kinase, and that activation of 
IGF-1R results in PI3-K mediated Akt phosphorylation therby ET-1 triggers the 
development and progression of prostate cancer cell (305). In VSMC, we have shown 
recently a requirement of IGF-1R in ET-1-induced PKB phosphorylation. These studies 
have shown that ET-1 was able to phosphorylate IGF-1R and inhibition of IGF-1R using 
AG1024, a selective pharmacological inhibitor of IGF-1R-PTK activity, attenuated both 
PKB phosphorylation and cell growth evoked by ET-1 (306). 
There is also some evidence indicating that transactivation of EGFR mediates the 
responses of IGF-1R in some cell types suggesting the existence of a cross-talk between 
IGF-R and EGF-R transactivation (307). Moreover, the studies showing that dominant 
negative or antisense oligonucleotide of IGF-1R are able to attenuate neointima 
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formation in an injured carotid artery rat model (308) and reduce AT1 receptors 
expression and function in spontaneously hypertensive rats (309) supports a potential 
pathogenic role of upregulated IGF-1R signalling in vascular disease.  
 Although several studies have shown that PDGFR undergoes tyrosine phosphorylation in 
response to Ang II in vitro and in vivo (310;311) an effect of ET-1 on PDGFR 
transactivation has not been established in VSMC (292) 
 
1-8-6-3 Mechanism of growth factor receptors transactivation  
 The mechanism by which vasoactive peptides transactivate growth factor 
receptors is not fully understood, yet several possible mechanisms have been suggested. 
The first mechanism involves metalloproteinase-induced cleavage of pro-heparin binding 
EGF (proHB-EGF) to HB-EGF which binds to the ectodomain of EGFR, and activates 
downstream signalling events (312). Both ET-1- and AngII-induced EGFR 
transactivation have been found to be sensitive to inhibition by a series of 
metalloproteinase inhibitors such as GM6001, doxycyclin and batimastat (291;312). 
These inhibitors were also shown to block downstream signaling induced by ET-1 and 
AngII in VSMC (291;313). Several matrix metalloproteinases have been identified and 
some of these have been implicated in cardiovascular pathophysiology. For example, an 
involvement of MMP2/9, a member of MMP family, in the development of pressure-
induced enhanced myogenic tone in mouse resistance artery has been reported (314). A 
role of ADAM 17, also known as tumor necrosis factor (TNF) alpha-converting enzyme 
(TACE), in mediating AngII-induced VSMC hypertrophy and EGFR transactivation was 
recently demonstrated (315). Interestingly, another ADAM family member, ADAM10, 
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was shown to have no role in AngII-induced EGFR transactivation in this system (315), 
whereas a requirement of ADAM 12 in AngII-induced cardiac hypertrophy and HB-EGF 
release was demonstrated (316). It seems that requirement of specific MMPs/ADAMs to 
release HB-EGF from pro-HB-EGF is dependent on cell type and physiological context. 
Although, MMPs are crucial for EGFR transactivation, a similar role of MMPs in 
PDGFR or IGF-1R transactivation remains to be established.   
In VSMCs, ET-1 and other vasoactive peptides mediate their responses through the 
generation of reactive oxygen species (ROS) (10;240). ROS have been suggested to serve 
as critical signaling molecules (317), and it may be possible that ROS generation could 
be among the mechanisms by which vasoactive peptides transactivate EGFR. In fact, by 
using different antioxidants, a requirement of ROS generation in ET-1 and Ang II-
induced phosphorylation of EGFR has been demonstrated (318).  There is also some 
suggestion for a role of ROS generation in MMP activation (319)  
The precise mechanism by which ROS contributes to the transactivation of growth factor 
receptors-PTKs is still unclear. However, in view of the ability of ROS to inhibit 
PTPases, such as PTP-1B(320)and SH-2 domain-containing tyrosine phosphatase -2 
(SHP-2) (321;322), it is possible that ROS can shift the equilibrium of the 
phosphorylation-dephosphorylation cycle, culminating in a net increase of tyrosine 
phosphorylation of R-PTK and /or other PTKs (284;323;324). The activated PTKs can 
thus promote the assembly of signaling components essential to trigger the ERK1/2 and 
PKB signaling pathways. It should be noted that a potential role of several non-receptors 
PTKs, such a Src and Pyk-2, in inducing AngII-induced EGFR transactivation has also 
been demonstrated (318;325).  
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2 Reactive oxygen species 
During the last few years, evidence has accumulated to suggest that the generation of 
reactive oxygen species (ROS) play a crucial role in the development and the progression 
of vascular dysfunction (326;327). More recent reports have confirmed this concept 
(328). Under oxidative stress conditions, excessive endogenous formation of ROS 
overcomes cellular antioxidant defense mechanisms, which results in ROS-initiated 
modification of lipids, proteins, carbohydrates and DNA (327). ROS are very small, 
rapidly diffusible, highly reactive molecules and include hydroxyl radicals (OH.), 
superoxide anion (O2.-) and non-radical derivative such as hydrogen peroxide (H2O2) 
(Fig.9). Mitochondria is among the sources of endogenous ROS, which convert 1-2 % of 
consumed molecular oxygen into superoxide anion (329). In VSMCs and endothelial 
cells, NADH/NADPH oxidases represent the most important source of O2.- (330). 
NADPH oxidase catalyzes the NADPH-dependent reduction of oxygen to O2.-, which is 
converted to H2O2 either by a protonation reaction or by the action of superoxide 
dismutase (SOD). H2O2 is reduced to H2O by catalase or glutathion peroxidase. Under 
certain conditions and in presence of metals, H2O2 can generate the extremely active OH. 
via Fenton or Haber-Weiss reaction (233) (Fig.9).  
 
2-1 ROS mediates ET-1 signaling 
ET-1 has been shown to activate NADPH oxidase, thereby increasing O2.- levels in 
endothelial cells (331) and cardiomyocytes (332) and stimulates O2.- production in 
pulmonary smooth muscle cells (333). Studies, from Fei lab, have shown that ET-1 can 
activate NADPH oxidase in VSMC (334) and that, in vivo, free radicals generated in this  
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                        Fig 9. Key steps in the production of reactive oxygen species 
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manner could play important roles in mineralocorticoid-induced hypertension, 
(98;335;336). Findings also suggest that ET-1 can increase O2.- levels via activation of 
NADPH oxidase in DOCA-salt rats (98). More recently, it has been documented that ET-
1 induces Ca2+ sensitization through activation of RhoA/ROK signaling induced by ROS 
in pulmonary VSM (337) and induces the activation of L-type Ca2+ channels via 
stimulation of NAD(P)H-derived superoxide production in cardiac myocytes (332). 
Increased ROS generation has been associated with a variety of cardiovascular 
pathologies (326) including hypertension (338) and atherosclerosis (339). Pathogenesis of 
cardiovascular diseases by activating ROS are thought to participate in the cellular 
signaling pathways responsible for promoting cell growth (340) and proliferation (234). It 
has been demonstrated that ET-1 induces JNK and p38mapk activation through ROS 
generation but not ERK1/2 (341). These findings are consistent with those of Fei et al. 
(334), who demonstrated that JNK activation but not ERK1/2 activation by ET-1 was 
significantly inhibited by antioxidants in rat smooth muscle cells. Conversely, a study 
demonstrated the involvement of ROS in ET-1-induced activation of ERK1/2 pathway as 
well as JNK and p38mapk in cardiac fibroblasts (234). Moreover, our laboratory has 
demonstrated a role of ROS in ET-1-induced activation of ERK1/2, PKB, and Pyk2 
signaling in VSMCs (10;284;324). 
ROS, such as H2O2 has been shown to induce increases in cytoplamic Ca2+ in a number of 
cell types including cells from vascular system (342). This finding was first reported by 
Hyslop et al. (343). The mechanism by which H2O2 induces intracellular Ca2+ is not fully 
clarified, however several hypotheses have been proposed. A potential role of  
extracellular Ca2+ entry into cells through voltage dependent Ca2+ channels and  
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intracellular Ca2+ from caffeine- and noradrenaline-sensitive stores in mediating H2O2-
induced   contractile responses of aortic ring has been suggested (344). It has also been 
reported that the activation of the tyrosine kinase c-Src contributes to the activation of 
store-mediated Ca2+ entry in platelets by H2O2 (345). In addition the increase in 
cytoplasmic Ca2+evoked by H2O2 in endothelial cells, appears to be derived totally from 
intracellular stores since BABTA-AM could attenuate this increase (346). Recently, 
Hecquet et al. have demonstrated a novel mechanism of H2O2-mediated disruption of 
endothelial barrier function that is attributable to a rise in intracellular Ca2+ mediated by 
Ca2+ entry through oxidant-sensitive channels named transient receptor potential 
melastatin (TRPM2) (347). 
 
2-2 ROS in cardiovascular pathophysiology  
Oxidative stress plays an important role in the pathophysiology of cardiovascular 
diseases such as hypertension, atherosclerosis, diabetes, cardiac hypertrophy and heart 
failure. Although several sources of ROS may be involved, a family of NADPH oxidases 
appears to be important for redox signaling. It has been reported that both NADPH 
oxidase subunit expression and activity are increased in Ang II-induced hypertension in 
rats (338;348) and the fact that ROS concentration is increased in hypertensive mice 
(349) indicate strongly the critical role of oxidative stress in hypertension. Treatment 
with an NADPH oxidase inhibitor decreases vascular O2- production and attenuates Ang 
II-induced elevation in blood pressure (350). Some subunits of NADPH oxidase have 
been reported to be implicated in hypertension. Nox1-deficient mice and p47phox- 
deficient mice have reduced vascular O2- production and blunted pressor responses to 
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Ang II (351;352) whilst transgenic mice overexpressing Nox1 in smooth muscle show 
enhanced O2- levels and blood pressure in response to Ang II (353). In SHR, the 
mechanism by which oxidative stress induced hypertension seems to be the enhanced 
expression of Gi proteins and adenylyl cyclase singaling in VSMCs (143). Furthermore, 
many other studies reported that antioxidants such as N-acetyl-cysteine, tempol and 
vitamins E and C prevent the development of hypertension in several animal models 
(354-356). 
 Evidence supports important pathophysiological roles for redox-sensitive signaling 
pathways in the processes underlying left ventricular hypertrophy, adverse left ventricular 
remodelling and congestive heart failure. Experimental (357) and clinical (358) studies 
have suggested that oxidative stress is increased in heart failure, and also have indicated 
that the degree of free radical production is linked to the severity of the disease.  
Hypertrophy of isolated cardiomyocytes induced by ET-1 or Ang II has been shown to 
involve increased ROS production (359). Similarly, the inhibition of cellular SOD 
activity, which leads to increased intracellular ROS levels, induces hypertrophy of 
isolated cardiomyocytes (360). Increased ROS production also promotes the development 
of interstitial and perivascular fibrosis as well as promoting increased extracellular matrix 
turnover, at least in part through the activation of MMP(361). Recently, evidence 
suggested that ROS may also induce specific changes in the function of proteins involved 
in myocardial excitation–contraction coupling, which include the sarcoplasmic reticulum 
Ca2+ ATPase pump, ryanodine receptor and contractile proteins (362). Thus it appears 
that ROS, via its effects on signaling pathways linked to hypertrophy, proliferation, and 
growth may contribute to various cardiovascular pathologies. 
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3 Nitric oxide   
NO is a free radical that was previously described as a non-prostaglandin, endothelium-
derived relaxing factor (EDRF) (40;363) and is involved in the regulation of a large 
number of biological processes (40;363). Efforts to understand the role of NO in the 
cardiovascular nervous and immune systems have revealed that it can modulate a variety 
of cellular and pathologies events including cell proliferation, growth, apoptosis, 
inflammation, kidney function, diabetes, oxidative stress and aging  (364;365). Most 
notably, NO has emerged as an important cardiovascular protective agent by its ability to 
exert anti-hypertrophic, anti-proliferative and anti apoptotic effect in cardiovascular 
system (366;367). 
 
3-1 Relationship between ET-1 and Nitric oxide  
Both ET-1 and NO are two endothelium- derived mediators that act as mutual antagonists 
in maintaining vascular tone as well as other physiological and pathological processes 
(368;369). In endothelial cells, the binding of ET-1 to ETB receptors, stimulates the 
release of NO which diffuses in to the smooth muscle cells and induces physiological 
effects. It has been suggested that long term exposure of endothelial cells to ET-1 
decreased NO levels by both degradation and attenuation of NO production resulting in 
endothelial dysfunction (370). It was also shown that endothelium-restricted 
overexpression of ET-1 caused endothelial dysfunction and a decrease in the level of NO 
(371). And the results from pre-clinical and clinical data further support this notion that 
the blockade of ET receptor function improves NO bioavailability and endothelial 
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function in pathological situations (370). However the precise molecular details by which 
NO antagonize the physiological effects of ET-1 in VSMCs remains to clarify. 
 
3-2 Formation of nitric oxide 
NO is formed from the aminoacid, L-arginine, in an oxidative reaction that consumes 
molecular oxygen and reducing equivalents in the form of NADPH (364;365;372) (Fig. 
10). Reaction products are NO, NADP+ and citrulline. NO is produced by the enzyme 
nitric oxide synthase (NOS), by the deamination of L-arginine. NOS is an enzyme 
requiring FAD, FMN, heme, Ca2+, calmodulin and 6(R)-tetra-hydro-L-biopterin (BH4) as 
cofactors (372). Since NO is a signaling hydrophobic molecule small enough to pass 
across the target-cell plasma membrane, NO cannot be stored and released as needed 
(363). NO acts locally because it has a short half-life (5-10 seconds) in the extracellular 
space before it is converted to nitrates and nitrites by oxygen and water (364). 
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                               Fig.10. The NOS-catalysed reaction   
                                From  (Andrew, P. J et al. Cardiovasc Res  43:521-531;1999) 
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3-3 NOS isoforms  
Three distinct NOS enzymes, each a product of a unique gene, have been identified and 
characterized (363;364;373). The neuronal form (nNOS or NOS-1) is a Ca2+-dependent 
enzyme found in neuronal tissue and skeletal muscle. Four splice variants of full lengh 
nNOS (nNOS) have been identified recently (nNOS, nNOS, nNOS and nNOS-2). 
The second isoform of NOS (iNOS or NOS-2) is inducible in a variety of cells and 
tissues in response to cytokine or endotoxin activation. Although, it is largely believed 
that in normal condition VSMCs do not express iNOS, regulation of iNOS gene 
expression in VSMCs has been reviewed (374). The third form, first found in vascular 
endothelial cells (eNOS or NOS-3), is also Ca2+-dependent, but differs from the neuronal 
form by its smaller size. eNOS is myristoylated and palmitoylated at the N-terminus. 
Those modifications are required to localize it to the plasmalemmal caveolae of 
endothelial cells. Human enzymes exhibit approximately 51-57 % homology at the 
aminoacid level (363;373). Structurally, all NOS isozymes consist of a carboxy-terminal 
reductase domain which binds the flavin cofactors. A Ca2+/calmodulin binding domain 
lies in the center followed by an oxygenase domain where binding of heme, O2, BH4 and 
arginine substrate take place (373).  
 
3-4 Nitric oxide function  
NO cellular signaling involves the regulated synthesis of NO by eNOS in the vascular 
endothelium, diffusion of NO into adjacent smooth muscle cell and activation of the 
soluble isoform of guanylate cyclase (sGC) (375). When NO binds to the pentacoordinate 
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ferrous heme of the sGC that appears to be uniquely tuned to interact with NO, a 
conformational change occur in the enzyme, stimulating its catalytic activity (376). NO 
causes relaxation of the smooth muscle by mediating the formation of cGMP that acts as 
a second messenger and activates the cGMP-dependent protein kinases (protein kinase G) 
(375;377), which in turn, facilitates the phosphorylation of various proteins as well as the 
reduction of intracellular calcium concentrations by different mechanisms  (378). 
Moreover, NO also targets many proteins either by nitrosylation of thiol residues, 
nitration of tyrosine or oxidizing DNA and proteins (378). Increasing evidence indicates 
also that NO may inactivate NADPH oxidase by inhibiting its assembling process, thus 
reducing the ROS levels (379). In higher concentrations, NO can react rapidly with 
superoxide (O2-) to form peroxynitrite (ONOO-), a potent oxidant with the potential to 
disrupt protein structures by nitrating the protein tyrosine residues (380). Although NO 
signaling is complex as a result of its interactions with ROS, heme groups on proteins, 
sulfhydryl groups, and other cellular targets, the activation of guanylate cyclase remains 
among the important pathway in mediating NO action (375).  
 
3-5 Guanylate cyclase  
Guanylate cyclase is an enzyme that catalyses the conversion of the guanosine 
triphosphate (GTP) to 3’-5’-guanosine monophosphate (cGMP). The guanylate cyclase is 
found in many cellular compartments (378). Two major forms of guanylate cyclases are 
known, the particulate guanylate cyclase and the soluble guanylate cyclase. It is generally 
believed that activation of soluble guanylate cyclase (sGC) is the principal intracellular 
event that initiates relaxation (381;382). The activity of the sGC is regulated by 
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nitrovasodilators, oxidation products of fatty acid and free radicals (383). sGC is a 
heterodimer of two subunits  and . Each subunit is divided in three different domains: 
the heme-binding domain, the catalytic domain and the dimerization domain 
(383)(Fig.12). N-terminal of each subunit contains heme as a prosthetic group which 
serves as a site for NO binding (383). sGC lacking the heme moiety, is not able to be 
activated by NO (383). Heme is attached to the protein portion of the enzyme by an 
imidazole axial ligand and binding of the heme is specific to the  subunit of the N-
terminal region (384;385). C-terminal of each subunit possesses a catalytic domain with a 
high homology sequence between the monomers (384;385). Coexpression of the catalytic 
domain of both subunits is necessary for GC activity. There is the dimerization domain 
between both domains described above that mediates the association of the heterodimer 
which is essential for the catalytic subunit (384;385). NO binding to the heme of the sGC 
results in the formation of a complex penta-coordinate heme-nitrosyl that breaks the axial 
histidine link (385). This conformational change exposes the catalytic site to GTP, 
leading to the activation of the enzyme and conversion of GTP to cGMP by sGC in the 
presence of Mg2+ or Mn2+ ions (375)  (Fig. 11). Recently, the vital importance of sGC for 
mammalian physiology was directly confirmed by generation of sGC knockout mice. The 
absence of sGC protein resulted in a significant increase in blood pressure (386)  
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Fig.11. Schematic representation of a soluble guanylate cyclase / heterodimer. The 
N-terminal region constitutes a haem-binding domain with His105 providing the axial 
ligand to the fifth coordinate of the haem-iron. The central portion of each subunit 
contains sequences which mediate dimerization of the monomers, a prerequisite for 
catalytic activity. The C-terminal region forms the catalytic domain, responsible for 
substrate binding (GTP) and conversion to cGMP.   
Adapted from (Hobbs et al.Trends Pharmacol Sci. 18:484-491, 1997)  
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3-6  Regulation of cGMP production 
In most tissues, the intracellular concentration of cGMP is determined by the rate of 
formation which is regulated by agonist-induced stimulation of a cyclase and hydrolysis 
of cGMP by a related group of phosphodiesterase E (PDE) (387)(Fig.12). There are at 
least seven known distinct mammalian PDE families. Each one differs from the other in 
biochemical and physical properties, responses to specific effectors, inhibitors and 
regulatory control mechanisms (387). Type V PDE has been isolated from a number of 
tissues including human platelets (388), trachea (389) and VSMC (390) and is commonly 
referred to as cGMP-specific PDE. PDE V is characterized by selectively hydrolyzing 
only cGMP, independently of Ca2+/calmodulin. Inhibitors of PDE V such as A02131-1 
have vasodilating and anti-aggregating properties, which may protect the vascular wall 
against arteriosclerotic changes (388).  
 
3-7 NO in signal transduction 
The endothelium serves as the principal physiological source of NO in blood vessels 
(391). As evidenced, NO contributes to the regulation of several hormone-mediated 
responses (392;393). In addition to its vasodilating effect, NO can also inhibit 
atherogenesis (363), thrombocyte aggregation (394) and VSMC proliferation (387;391) 
and migration (395). There is also increasing body of evidence suggesting that NO is able 
to antagonize the physiological and pathophysiological effects (162;375) of growth 
factors and vasoactive peptides such as EGF (387), PDGF (396) and bFGF (395). This is 
probably achieved by inhibiting one or several of the signaling events induced by these 
factors (363;391;395;397). According to several studies, mitogens such as ET-1 stimulate  
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                              Fig.12. The nitric oxide/cGMP signal transduction  
                                                From  (Lloyd-Jones  and Bloch . Annu Rev Med 47: 365-375, 1996)  
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the synthesis of DNA and cell proliferation by activating the phosphorylation cascade of 
MAPK (234;239;398). The potential mechanism that could modulate VSMC proliferation 
is the release of NO by the endothelium either via a cGMP-dependent (375;387) or a 
cGMP-independent mechanisms (399;400). In cardiomyocytes, ET-1-induced protein 
synthesis (401;402) has also been shown to be inhibited by NO (403). Furthermore, NO 
was found to suppress the Ang II-induced activation of three major MAPKs, ERK1/2, 
p38mapk and JNK (404) as well as Pyk2 (393) in cardiac fibroblasts. However, it is not 
known whether NO, similar to its effect on growth factor and Ang II-induced responses, 
can also modulate signaling events triggered by ET-1 receptor activation in VSMC. In 
smooth muscle-derived A7r5 cells, NO has been shown to regulate PDGF-induced 
activation of PKB (392). These data implicate PKB signaling cascade as an important 
mitogenic pathway that is subjected to modulation by NO in VSMC (392). However, the 
role of NO/cGMP in modulating PKB signaling pathway in response to ET-1 has not yet 
been investigated in any cell type. 
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4 Hypothesis and objectives  
As discussed above, ET-1 and NO are very potent active molecules, by virtue of their 
ability to regulate various cardiovascular function they play an important role in health 
and diseases. ET-1 activates multiple signaling pathways including MAPK and PI3-
K/PKB which mediate the hypertrophic and proliferative responses in VSMC. An 
important role of ROS generation in mediating the effect of ET-1 has been demonstrated 
and both ROS and ET-1 have been reported to activate similar signaling pathways. 
Moreover, Ca2+ has emerged as a key second messenger to transduce the effect of ET-1 
as well as ROS. Furthermore, NO has been shown to serve as an anti-hypertrophic and 
serve as and anti-proliferative agent in many cell types. However, the precise mechanism 
by which Ca2+ contribute to ET-1 and ROS-induced signaling and physiological 
responses, and how NO can modulate these effects in VSMCs remain unexplored 
therefore the following studies have been undertaken to better understand this process. 
Thus, the purposes of the present studies were to elucidate: 
1. The implication of CaMKII which is downstream effector Ca2+ action in ET-1 
induced ERK1/2 and PKB signaling in VSMCs.  Therefore, the first objective of 
the present studies was to examine the role of CaMKII in ET-induced signaling as 
well as growth and proliferation in VSMCs. 
2. Since ET-1 mediates its effects through the generation of ROS, we investigated 
the role of CaMKII in H O  induced ERK and PKB phosphorylation as well as 
IGF-1R phosphorylation. 
2 2
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3. To better understand the molecular mechanism by which NO antagonizes the anti 
proliferative and hypertrophic effect of ET-1, we have also investigated the effect 
of NO system on ET-1-sensitive signaling. In these studies, we first elucidated the 
role of NO on key components of ET-1 signaling system, ERK1/2, PKB and Pyk-
2 as well as protein synthesis in VSMCs. We then used 8-Bromo-cGMP, a cyclic 
GMP analogue and ODQ, an inhibitor of sGC, to examine whether NO acting 
through a cGMP-dependent mechanism.  
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Will be submitted soon to Cardiovascular Research 
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Abstract  
We have shown earlier that in vascular smooth muscle cells (VSMC), H2O2-
induced activation of extracellular signal-regulated kinases 1 and 2 (ERK1/2) and protein 
kinase B (PKB), two key mediators of growth-promoting and proliferative responses, are 
mediated through Ca2+ and Calmodulin (CaM)-dependent downstream signals. Moreover, 
endothelin-1 (ET-1), a powerful vasoactive peptide with a pathogenic role in vascular 
disease, requires H2O2 generation to elicit its responses. Therefore, in the present studies, 
we have investigated a possible role of CaM and its effector, Ca2+/CaM-dependent 
protein kinaseII (CaMKII) in mediating the ET-1-induced ERK1/2 and PKB 
phosphorylation by using pharmacological inhibitors, CaMKII inhibitor peptide and 
small interfering RNA (siRNA) technique. W-7 and calmidazolium, antagonists of CaM, 
as well as KN-93, a specific inhibitor of CaMKII, attenuated ET-1-induced ERK1/2 and 
PKB phosphorylation in a dose-dependent fashion.  However, KN-92, an inactive 
analogue of KN-93 was without effect.  Transfection of VSMC with CaMKII inhibitory 
peptide (AA 281-309) corresponding to auto-inhibitory domain (AID) of CaMKII, 
attenuated ET-1-induced phosphorylation of ERK1/2 and PKB. Furthermore, significant 
knock-down of CaMKII expression by using CaMKII siRNA and reduced ET-1-
induced ERK1/2 and PKB phosphorylation, whereas, control siRNA was without any 
effect on these events. Blockaded of CaM and CaMK-II by W-7 and KN-93, respectively, 
significantly reduced ET-1-induced increase in protein and DNA synthesis. In addition, 
ET-1 also induced Thr286 phosphorylation of CaMKII which is associated with its 
enhanced catalytic activity. Taken together, these data demonstrate that CaM/CaMKII 
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plays an important role in mediating the stimulatory action of ET-1 on ERK1/2 and PKB 
phosphorylation as well as on hypertrophic and proliferative responses in VSMC.    
 
Key words:  Cell signaling, endothelin-1, calmodulin, CaMKII, VSMC.  Hypertrophy, 
proliferation: ERK-1/2, PKB/Akt 
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Introduction 
 Endothelin-1 (ET-1) is a potent vasoconstrictor peptide (1) which also exhibits 
mitogenic activity in vascular smooth muscle cells (VSMC) (2-4).  A possible role for 
ET-1 in the pathogenesis of many diseases, such as atherosclerosis (5), hypertension (6) 
and restenosis after angioplasty has been suggested (7). ET-1 exerts its biological 
actions through the activation of two receptor subtypes, ETA and ETB (8, 9). Both 
receptors belong to a large family of transmembrane guanine nucleotide-binding 
protein-coupled receptors (GPCRs). ETA receptors are highly expressed in VSMC but 
are also found in cardiomyocytes, fibroblasts, hepatocytes, adipocytes, osteoblasts and 
brain neurons (8, 10) and exhibit higher affinities for ET-1 and ET-2 than for ET-3 (8). 
ETB receptors exist predominantly in endothelial cells and smooth muscle cells, but are 
also found in cardiomyocytes, hepatocytes, fibroblasts, osteoblasts, different epithelial 
cells and neurons and have equal subnanomolar affinities for all ET iso-peptides (9).  
ET-1 binding to ETA receptors on smooth muscle produces vasoconstriction, cell 
growth and cell adhesion (11) whereas the binding of ET-1 to endothelial ETB receptors 
stimulates the release of nitric oxide and prostacyclin (12, 13).  
ET-1 exerts its effects through multiple signaling pathways which include Ca2+ (14), 
mitogen-activated protein kinases (MAPKs) including extracellular signal-regulated 
kinases 1/2 (ERK1/2), c-Jun-NH2-terminal kinase (JNK) and p38mapk (15-19) and 
Akt/phosphatidylinositol 3-kinase (PI-3K)/protein kinase B (PKB) (19, 20). Activation 
of receptor and non-receptor protein tyrosine kinases (PTKs) in transducing ET-1-
induced signaling responses have also been suggested (18, 21-24). PTKs activated by 
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ET-1 include epidermal growth factor (EGF) (24), c-Src (21, 23, 25) and a Ca2+-
dependent PTK, Pyk2 (26). 
Several studies have demonstrated that reactive oxygen species (ROS) play an 
important role in mediating the signals of several growth factors, peptides hormones, 
and cytokines, such as platelet-derived growth factor, EGF, angiotensin II, insulin and 
interleukin-1. ET-1 has also been shown to augment ROS production in VSMC (27, 
28). H2O2, an important ROS molecule, has been reported to activate both MAPKs and 
PKB signaling in many cell types including VSMC (29-31). We have shown earlier that 
Ca2+ and CaM are essential to trigger H2O2- induced ERK1/2, p38 and PKB 
phosphorylation in A-10 VSMC (32). CaM exerts its effects through Ca2+/ CaM 
dependent protein (CaMKII) which is a multifunctional serine/threonine protein kinase 
and is believed to transduce the downstream effects of Ca2+/CaM (32). CaMKII is 
maintained in an inactive state by an autoinhibitory domain (AID), the binding of 
Ca2+/CaM complex to the CaM binding domain reverses this auto inhibition by 
changing the confirmation of CaMKII inducing its autophosphorylation at Thr286 (33). 
 
Angiotensin II (Ang II) has been shown to increase CaMKII phosphorylation and 
activity, and a role of CaMKII in AngII-induced activation of ERK1/2 has been 
demonstrated in VSMC (34). However, a role of CaMKII in mediating ET-1-induced 
ERK1/2 and PKB phosphorylation and its effect on hypertrophic and proliferative 
responses in VSMC remains unexplored. Therefore, in the present studies, by using a 
series of pharmacological inhibitors and genetic approaches, we investigated the 
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involvement of CaM and CaMKII in ET-1-induced ERK1/2 and PKB 
phosphorylation, as well as protein and DNA synthesis, in A-10 VSMC. 
Materials and Methods 
Materials
ET-1 was purchased from American Peptide Inc (USA). BQ-123, BQ-788, 
calmidazolium, W-7, KN-93, KN-92 and CaMKII autoinhibitory domain (AID) specific 
peptide inhibitor (AA 281-309, autoinhibitory peptide (AIP)) were obtained from 
Calbiochem and Lipofectamine was form Invitrogen, Canada. Monoclonal phospho-
specific- Thr202 -Tyr204-ERK1/2 antibody, polyclonal ERK1/2 antibody, CaMKII siRNA 
(catalogue number sc-29901), control siRNA (catalogue number sc-37007), transfection 
reagent for siRNA (catalogue number sc-29528), phospho-specific-Thr286-CaMKII, anti-
CaMKII, and -actin antibodies were from Santa Cruz Biotech (Santa Cruz, CA). 
CaMKII siRNA is a pool of 3 target-specific, 20-25 nucleotide siRNAs designed to 
knock down gene expression of CaMKII. The non-specific siRNA (scrambled) consist 
of non-targeting 21 nucleotides with no homology to rat genes. The phospho-specific-
Ser473-PKB and total PKB antibodies as well as horseradish peroxidase-conjugated anti-
rabbit antibodies were procured from New England Biolabs (Beverly, MA). The 
enhanced chemiluminescence (ECL) detection system kit, (3H) Thymidine and L-(4,5-
3H) leucine were from was from Amersham Pharmacia Biotech (Baie d’Urfé, QC, 
Canada).  
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Methods
Cell culture 
VSMC derived from embryonic rat thoracic aorta A-10 cells were maintained in 
culture with Dulbecco’s modified eagle medium (DMEM) containing 10% fetal bovine 
serum at 370C in a humidified atmosphere of 5% CO2 as described earlier (26). The cells 
were grown to 80-90% confluence in 60-mm plates and incubated in serum-free DMEM 
5h prior to the treatments. 
Transfection with CaMKII inhibitory peptide 
A-10 VSMCs at 80-90 % confluence were transfected with a CaMKII-specific AID 
domain inhibitory peptide (2ng/ml) by using lipofectamine (4μg/ml) (35). Transfections 
were performed in serum and antibiotics-free media DMEM for 2h then 10% of serum 
was added. Protein phosphorylation by ET-1 in peptide-transfected cells was examined 
48h later. 
siRNA transfection protocol 
A-10 VSMCs at 80-90 % confluence were transfected with CaMKII siRNA or control 
scrambled siRNA (final concentration of CaMKII or scrambled, non-specific siRNA 
was 70 nM) according to the manufacturer’s protocol. Transfections were performed in 
serum and antibiotics-free DMEM. A mixture of CaMKII siRNA or control scrambled 
siRNA and transfection reagent was added to cells and incubated for 6h at 37oC then 
serum was added to reach 10% of FBS. Cells were incubated for an additional 48h before 
stimulation with ET-1. 
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Cell lysis and Immunoblotting 
Cells incubated in the absence or presence of various agents were washed twice with ice-
cold PBS and lysed in 200 l of buffer (25 mM Tris-HCl, pH 7.5, 25 mM NaCl, 1 mM 
Na orthovanadate, 10 mM Na fluoride, 10 mM Na pyrophosphate, 2 mM benzamidine, 2 
mM ethylenebis(oxyethylenenitrolo)-tetraacetic acid, 2 mM ethylenediamine tetraacetic 
acid, 1 mM phenylmethylsulfonyl fluoride, 10 g/ml aprotinin, 1% Triton X-100, 0.1% 
sodium dodecyl sulfate (SDS), and 0.5 g/ml leupeptin) on ice. The cell lysates were 
centrifuged at 12,000g for 10 min at 40C. Protein concentrations were measured by 
Bradford assay. Equal amounts of protein were subjected to 7.5% SDS-polyacrylamide 
gel (SDS-PAGE), transferred to PVDF membranes (Millipore, MA, USA) and incubated 
with respective primary antibodies, (monoclonal phospho-specific- Thr202 -Tyr204-
ERK1/2 antibody (1:4,000), polyclonal phospho-specific-Ser473-PKB antibody (1:1,000). 
phospho-specific-Thr286-CaMKII antibody (1:2,000)). The antigen-antibody complex was 
detected by a horseradish peroxidase-conjugated second antibody (1:2000), and protein 
bands were visualized by ECL. The intensity of specific bands was quantified by NIH 
Image software as described previously (36). 
Measurement of [Methyl 3H-4] thymidine incorporation: DNA Synthesis in the cells 
was evaluated by incorporation of [Methyl 3H-4] thymidine into cells.  A10 VSMCs at 
80-90% confluence were serum-starved for 16hrs to induce cell quiescence.  The cells 
were then incubated with ET-1 (100nM) alone or after pretreatment with calmidazolium 
(10M) or KN-93, (10M) or KN-92 (10M) for 30 min, left to incubate for another 
24hrs, in [3H] thymidine (1ci/dish).  Cells were washed twice with cold PBS, and 1 ml 
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of cold 5% trichloroacetic acid was added for 30 min to precipitate protein.  The 
precipitates were subsequently washed twice with ice cold water and resuspended in 
500ml of 0.4 M NaOH and radioactivity incorporated into DNA was determined by a 
liquid scintillation counter (28). 
[3H] Leucine incorporation:  Protein Synthesis was assessed by incorporation of [3H] 
leucine into protein.  A10 VSMCs at 80-90% confluence were serum-starved for 16hrs to 
induce cell quiescence.  The cells were treated with ET-1 (100nM) alone or after 
pretreatment with calmidazolium, or KN-93 or KN-92 for 30 min, and left to incubate for 
another 24 hrs.  [3H] leucine, 1ci/dish, was added  at the same time as ET-1.  Cells were 
washed twice with cold PBS, and 1 ml of cold 5% trichloroacetic acid was added for 30 
min to precipitate protein. The precipitates were subsequently washed twice with ice cold 
water and resuspended in 500 l of 0.4 M NaOH and radioactivity incorported into 
protein was determined by liquid a scintillation counter (28). 
Statistics                
The data are means ± SE of at least three individual experiments. Statistical significance 
was determined with paired or unpaired Student’s t test and p<0.05 was considered 
significant. 
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Results 
ET-1 induces ERK1/2, PKB and CaMKII phosphorylation via ETA and not ETB 
receptors in A-10 VSMCs 
Several studies have reported the involvement of ETA receptors in ET-1-induced 
signalling in VSMC.  However, specific involvement of ETA receptors in ET-1-induced 
PKB activation has not been investigated.  Therefore, by using BQ-123 and BQ-788, 
blockers of ETA and ETB receptors, respectively, we assessed the specific contributions 
of these receptors in mediating the effect of ET-1 on PKB phosphorylation. As shown in 
Fig.1, pretreatment of A-10 VSMC with BQ-123 for 30 min caused a significant 
reduction in ET-1-induced ERK1/2 (Fig.1A) and PKB (Fig. 1B) phosphorylation 
whereas; BQ-788 was without effect.  These data established the implication of ETA and 
not ETB receptor subtype in ET-1-induced PKB and ERK1/2 phosphorylation. The two 
inhibitors alone did not affect the basal phosphorylation of ERK1/2 and PKB. 
Dose-dependent attenuation of ET-1-induced ERK1/2 and PKB phosphorylation by 
CaM and CaMKII inhibitor in A-10 VSMCs. 
We have shown earlier that CaM is required for H2O2-induced PKB phosphorylation in 
A-10 VSMC (32). Since ET-1 induced ROS production we examined the involvement of 
both calmodulin and its downstream effecter, CaMKII, in ET-1-induced ERK1/2 and 
PKB phosphorylation. As shown in Fig.2, pretreatment of A-10 VSMCs with W-7 and 
calmidazolium, specific inhibitors of CaM, for 30 min, dose-dependently attenuated ET-
1-induced phosphorylation of these two signaling component. However, PKB appeared to 
be more sensitive to the inhibitory effect of both W-7 and calmidazolium than ERK1/2. 
Almost complete attenuation of ET-1-stimulated phosphorylation of PKB was observed 
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at 10 μM of W-7 or calmidazolium (Fig.2 A and C). In contrast, a higher concentration of 
these inhibitors was required to inhibit ET-1-enhanced phosphorylation of ERK1/2 (Fig.2 
B and D). We next investigated the effect of the blockade of CaMKII on ET-1-induced 
responses using KN-93.  KN-93 inhibits CaMKII activity by competitively binding to 
CaM binding domain of CaMKII.  As shown in Fig.3, KN-93 treatment dose-dependently 
inhibited ET-1-induced ERK-1/2 (panel B) and PKB (panel A) phosphorylation.  
However, KN-93 inhibited the PKB phosphorylation more potently than the 
phosphorylation of ERK1/2.  (Fig.3 A and B). 
CaMKII inhibitory peptide (AIP) and CaMKII siRNA attenuates ET-1 -induced 
ERK1/2 and PKB phosphorylation. 
To provide additional proof for the involvement of CaMKII in ET-1-induced responses, 
we have used a peptide corresponding to the autoinhibitory domain (AID) of CaMKII 
(AA 281-309) (AIP) and siRNA approaches to confirm the results obtained using 
chemical inhibitors.  Transfection of A-10 VSMC for 48h with this AIP markedly 
reduced ET-1-induced phosphorylation of ERK1/2 and PKB (Fig.4).  In addition, we also 
used siRNA of CaMKII to knock-down CaMKII expression in A-10 VSMC, to 
evaluate its role in ET-1-induced responses.  As shown in Fig.5, transfection of A-10 
VSMC with siRNA of CaMKII resulted in about 70% reduction in the expression of 
CaMKII protein, whereas control siRNA to CaMKII was without effect.  siRNA of 
CaMKII also had no effect on the expression of -actin (Fig.5).  The cells with siRNA-
induced knock-down of CaMKII showed a significant inhibition in the phosphorylation 
of ERK1/2 (Fig.6B) and PKB (Fig.6A) in response to ET-1. 
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ET-1-induced CaMKII phosphorylation in A-10 VSMC 
Ang II has been shown to activate CaMKII (37) in VSMC, therefore, we wished to 
investigate if ET-1 would exert a similar effect on CaMKII.  This was tested by 
determining the Thr286 phosphorylation of CaMKII, which has been shown to enhance its 
catalytic activity.  As shown in Fig.7 treatment of A-10 VSMC with ET-1 resulted in a 
rapid and sustained phosphorylation of CaMKII, which was detectable within 2 min and 
remained elevated for up to 30 min.  
 
CaM and CaMKII inhibitors attenuated ET-1-stimulated [3H]leucine and  
[3H]thymidine  incorporation. 
Since activation of ERK1/2 and PKB signaling has been implicated in mediating the 
hypertrophic and proliferative responses of ET-1 (38), we next examined whether there 
was a correlation between CaMKII-induced inhibition and ET-1-induced PKB and 
ERK1/2 phosphorylation and protein and DNA synthesis. As shown in Fig.8, ET-1 
increased both [3H]leucine (Fig.8A) and [3H]thymidine (Fig.8B) incorporation into 
cellular protein and DNA, respectively, by about 50% over control. However, the 
inhibition of CaM by using W-7, or the inhibition of CaMKII by KN-93 reduced ET-1-
induced [3H]leucine and [3H]tymidine incorporation to almost basal level.  KN-92 was 
without any effect on protein and DNA synthesis induced by ET-1in A-10 VSMC.  
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Discussion 
 
Since ET-1 rises intracellular Ca 2+ concentration via PLC/DAG/IP3 pathway, in VSMC 
(19) and Ca2+ exerts many of its effect through CaM and CaMKII, we investigated the 
role of CaMKII in mediating the responses of ET-1 in VSMC. By using three different 
approaches, i.e. use of pharmacological inhibitors, a CaMKII AIP and siRNA techniques 
here, we have demonstrated that CaMKII mediates the effect of ET-1 on ERK1/2 and 
PKB phosphorylation in A-10 VSMC. By using pharmacological inhibitor alone such as, 
KN-93, earlier studies have reported that AngII and Ca2+ elevation agents, such as 
ionomycin, exert their effects on ERK1/2 phosphorylation via CaM-dependent pathways 
in VSMC (34, 37). However, our studies, by using multiple approaches, have provided 
the first evidence to suggest an involvement of CaMKII in mediating the effect of ET-1 
on ERK1/2 and PKB phosphorylation in A-10 VSMC. 
We have also shown that ET-1 induced the phosphorylation of CaMKII in Thr286.  
The phosphorylation of this site in AID of CaMKII has been shown to activate the 
catalytic activity of CaMKII (39).   Since Ca2+ ionophore ionomycin has also been shown 
to increase the phosphorylation of CaMKII in VSMC  (40), it is possible to ET-1-
induced Ca2+ release (through Ca2+/CaM binding to AID) contributes to this 
autophosphorylation reaction in A10 VSMC.  However, the precise mechanism by which 
activated CaMKII participates in the activation of ERK1/2 and PKB remains to be 
elucidated.  ET-1 has been shown to activate a Ca2+-dependent PTK, which has been 
linked with the activation of ERK1/2 and PKB pathways  (41, 42).  Since ET-1 activates 
Pyk-2 in A10 VSMC, it is possible that CaMKII, through some yet unidentified 
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intermediary protein, contributes to the activation of Pyk-2 and/or other PTKs, which 
eventually activate ERK1/2 and PKB signalling pathways. 
It is well known that ERK1/2 and PKB play a crucial role in mediating VSMC 
hypertrophy and proliferation  (43).  Interestingly, the present study shows an inhibitory 
effect of W-7 and KN-93 on ET-1-induced DNA and protein synthesis.  It may therefore 
be suggested that the ability of CaMKII to stimulate ERK1/2 and PKB pathways may 
serve as a potential mechanism by which ET-1 induces growth and proliferative 
responses in VSMC. 
A role of CaMKII in several pathophysiological events in different cell type, such 
as VSMC (44) and cardiomyocytes (45) has been suggested and in heart, ET-1-induced  
cardiomyocyte hypertrophy has been linked to CaMKII activation  (45).  Moreover, 
studies showing that inhibition of CaMKII by using KN-93 improved vascular 
dysfunction (46) in animal models of diabetes or in AngII-induced hypertension (47), 
suggesting that abberant activation of CaMKII may be involved in these vascular 
pathologies. 
 
In conclusion, we have shown that CaMKII plays an important intermediary role 
in activating ET-1-induced signalling of ERK1/2 and PKB pathways, which are also 
intimately linked to its hypertrophic and proliferative responses.  It may be suggested that 
by regulating the growth promoting and hypertrophic events, CaMKII plays an important 
role in vascular pathophysiology. 
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Figures legends  
Figure 1. Effect of BQ-123 and BQ-788 inhibitors of ETA and ETB receptors, 
respectively on ET-1-induced ERK1/2 and PKB phosphorylation in A-10 VSMCs. 
Serum-starved quiescent A-10 cells were pretreated with or without BQ-123 or BQ-788 
10M for 30 min followed by 100nM of ET-1 for 5 min. Cell lysates were 
immunoblotted by phospho-specific-Thr202 -Tyr204-ERK1/2 antibodies (A), and phospho-
specific-Ser473-PKB antibodies (B), as shown in the middle panels of each section. Blots 
were also analyzed for total ERK1/2 and PKB (bottom panels of each section). Top 
panels, (bar diagrams) in each section represent average data quantified by densitometric 
scanning of immunoblots. Values are the means  SE of at least 3 independent 
experiments and are expressed as percentage phosphorylation where phosphorylation 
observed with ET-1 alone is defined as 100%. *P< 0.05 considered as statistically 
significance versus ET-1 stimulation alone. 
Figure 2. Dose-dependent effect of W-7 and calmidazolium, two calmodulin inhibitors, 
on ET-1-induced ERK1/2 and PKB phosphorylation in A-10 VSMCs. Serum-starved 
quiescent A-10 cells were pretreated with or without the indicated W-7 (section A and B) 
or calmidazolium (section C and D)  concentrations for 30 min followed by 100nM of 
ET-1 for 5 min. Cell lysates were immunoblotted by phospho-specific-Ser473-PKB 
antibodies (A and C) and phospho-specific- Thr202 -Tyr204-ERK1/2 antibodies (B and D), 
as shown in the middle panels of each section. Blots were also analyzed for total ERK1/2 
and PKB (bottom panels of each section). Top panels (bar diagrams) in each section 
represent average data quantified by densitometric scanning of immunoblots. Values are 
the means  SE of at least 3 independent experiments and are expressed as percentage 
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phosphorylation where phosphorylation observed with ET-1 alone is defined as 100%. 
*P< 0.05 considered as statistically significance versus ET-1 stimulation alone.  
Figure 3. Dose-dependent effect of KN-93, CaMKII inhibitor, on ET-1-induced ERK1/2 
and PKB phosphorylation in A-10 VSMCs. Serum-starved quiescent A-10 cells were 
pretreated with or without the indicated KN-93 concentrations for 30 min followed by 
100nM of ET-1 for 5 min. Cell lysates were immunoblotted by phospho-specific-Ser473-
PKB antibodies (A) and phospho-specific- Thr202 -Tyr204-ERK1/2 antibodies (B), as 
shown in the middle panels of each section. Blots were also analyzed for total ERK1/2 
and PKB (bottom panels of each section). Top panels (bar diagrams) in each section 
represent average data quantified by densitometric scanning of immunoblots. Values are 
the means  SE of at least 3 independent experiments and are expressed as percentage 
phosphorylation where phosphorylation observed with ET-1 alone is defined as 100%. 
*P< 0.05 considered as statistically significance versus ET-1 stimulation alone.  
Figure 4. Effect of an inhibitory peptide of CaMKII (AA 281-309) on ET-1-induced 
ERK1/2 and PKB phosphorylation in A-10 VSMCs. A-10 VSMC were transfected, using 
lipofectamin, with an  inhibitory peptide for 48h prior stimulation of ET-1 (100nM, 
5min). The effect of lipofectamin on ET-1-induced ERK1/2 and PKB phosphorylation 
was used as a control. Cell lysates were immunoblotted by phospho-specific-Ser473-PKB 
antibodies (A) and phospho-specific- Thr202 -Tyr204-ERK1/2 antibodies (B), as shown in 
the middle panels of each section. Blots were also analyzed for total ERK1/2 and PKB 
(Bottom panels of each section). Top panels (bar diagrams) in each section represent 
average data quantified by densitometric scanning of immunoblots. Values are the means 
 SE of at least 3 independent experiments and are expressed as percentage 
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phosphorylation where phosphorylation observed with ET-1 alone is defined as 100%. 
*P< 0.05 considered as statistically significance versus ET-1 stimulation alone.  
Figure 5. CaMKII siRNA knocks down the expression of CaMKII in A-10 cells.    
A-10 VSMC were transfected, using Santa Cruz transfection reagent (sc-37007), with 
CaMKII siRNA (sc-29901) or control siRNA (sc-37007)for 24hrs, and cell lysates were 
immunoblotted with CaMKII or -actin antibodies. Values are the means  SE of 3 
independent experiments and are expressed as % expression over basal. *P< 0.05 versus 
control siRNA. 
Figure 6. Effect of CaMKII siRNA on ET-1-induced ERK1/2 and PKB phosphorylation 
in A-10 VSMCs. A-10 VSMC were transfected with CaMKII siRNA (cat #sc-37007) 
(70nM) or control siRNA for 24h prior to stimulation with ET-1 (100nM, 5min). Cell 
lysates were immunoblotted by phospho-specific-Ser473-PKB antibodies (A) and 
phospho-specific-Tyr204-ERK1/2 antibodies (B), as shown in the middle panels of each 
section. Blots were also analyzed for total ERK1/2 and PKB (Bottom panels of each 
section). Top panels (bar diagrams) in each section represent average data quantified by 
densitometric scanning of pERK1/2 or pPKB immunoblots. Values are the means  SE of 
at least 3 independent experiments and are expressed as percentage phosphorylation 
where phosphorylation observed with ET-1 alone is defined as 100%. *P< 0.05 versus 
ET-1 alone. 
Figure.7. Time course of ET-1-induced CaMKII phosphorylation in A-10 VSMC. 
Serum-starved quiescent A-10 cells were treated with ET-1 100nM for indicated times. 
Cell lysates were immunoblotted with phospho-specific-Thr286-CaMKII antibodies 
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(middle panel) and total CaMKII (Bottom panel). Top panels (bar diagrams) represent 
average data quantified by densitometric scanning of p-CaMKII immunoblots. Values are 
the means  SE of at least 3 independent experiments and are expressed as fold increase. 
*P< 0.05 versus time 0 min.  
Figure 8. Effects of W-7 and KN-93 on ET-1-induced [3H]leucine and [3H]thymidine  
incorporation. Serum-starved quiescent A-10 cells were stimulated with ET-1 (100 nM). 
Cells were pretreated or not with 10 M of W-7 or KN-93 for 30 min before ET-1 
stimulation, then the cells were labeled to equilibrium with [3H]leucine or [3H]thymidine  
as described in Materials and Methods. Values are the means  SE of 3 independent 
experiments and are expressed as percentage of change in [3H]leucine (A) or 
[3H]thymidine (B)  incorporated into total cellular proteins or DNA over the basal values. 
*P< 0.05 versus control and † p <0.05 versus ET-1 alone.  
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Abstract  
We have shown earlier a requirement of Ca2+ and calmodulin (CaM) in H2O2-induced 
activation of extracellular signal-regulated kinases 1 and 2 (ERK1/2) and protein kinase 
B (PKB), key mediators of growth promoting, proliferative and hypertrophic responses in 
vascular smooth muscle cells (VSMC). Since the effect of CaM is mediated through 
CaM-dependent protein kinaseII (CaMKII), we have investigated here the potential role 
of CaMKII in H2O2-induced ERK1/2 and PKB phosphorylation by using 
pharmacological inhibitors of CaM and CaMKII, a CaMKII inhibitor peptide and siRNA 
knockdown strategies for CaMKII. Calmidazolium and W-7, antagonists of CaM as 
well as KN-93, a specific inhibitor of CaMKII, attenuated H2O2-induced responses on 
ERK1/2 and PKB phosphorylation in a dose-dependent fashion. Similar to H2O2, 
calmidazolium and KN-93 also exhibited an inhibitory effect on glucose/glucose oxidase 
(G/GO)-induced phosphorylation of ERK1/2 and PKB in these cells.  Transfection of 
VSMC with CaMKII auto-inhibitory peptide (AIP) corresponding to auto-inhibitory 
domain (AA 281-309) of CaMKII and with siRNA of CaMKII, attenuated H2O2-
induced phosphorylation of ERK1/2 and PKB. In addition, calmidazolium and KN-93 
blocked H2O2-induced Pyk2 and insulin-like growth factor-1 receptor (IGF-1R) 
phosphorylation. Moreover, treatment of VSMC with CaMKIIsiRNA abolished the 
H2O2-induced IGF-1-R phosphorylation. H2O2 treatment also induced Thr286 
phosphorylation of CaMKII which was inhibited by both calmidazolium and KN-93. 
These results demonstrate that CaMKII plays a critical upstream role in mediating the 
effect of H2O2 on ERK1/2, PKB and IGF-1R phosphorylation.  Key words:  Oxidative 
stress signaling, H2O2, VSMC, CaMKII, ERK1/2, PKB, Pyk-2, IGF-1R. 
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Introduction 
Oxidative stress is believed to play a critical role in the pathogenesis of several 
diseases such as cancer [1], diabetes [2,3] and cardiovascular pathophysiology, including 
hypertension and atherosclerosis[4-6]. Excessive endogenous formation of reactive 
oxygen species (ROS) overcomes cellular antioxidant defense mechanisms, leading to 
oxidative stress. Superoxide anion (O2•) and hydrogen peroxide (H2O2) are among the 
most important ROS molecules. In VSMC, NAD(P)H oxidase is one of the primary 
enzymes responsible for the generation of O2• [7]. NAD(P)H oxidase catalyzes O2• 
production by the one electron reduction of O2 where NAD(P)H is the electron donor. 
Under physiological conditions, O2• undergoes dismutation either spontaneously or by a 
reaction catalyzed by superoxide dismutase (SOD) to produce H2O2 which is more stable 
than O2•and is a freely diffusible ROS molecule [8]. Normally H2O2 is scavenged by 
catalase and glutathione peroxidase to produce H2O [9,10]. However, an aberration either 
in generation or scavenging of H2O2 or other ROS molecules has been suggested to 
contribute the pathophysiology of various diseases including cardiovascular diseases[4-
6]. A direct role of H2O2 in angiotensin (AngII)-induced vasculature hypertrophy has also 
been suggested recently in a model of hypertensive vascular disease [11]. Exogenous 
H2O2 activates several signaling protein kinases such as mitogen activated protein kinases 
(MAPK) and protein kinase B (PKB) [12-15] which have been proposed to play key roles 
in mediating the hypertrophic response in VSMC [16]. Although the precise mechanism 
and intermediary steps by which H2O2 activates these signaling pathways remain poorly 
characterized, our earlier studies have reported that tyrosine phosphorylation of -subunit 
IGF-1R is an important step in tranducing the effect of H2O2 on the phosphorylation of 
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ERK1/2, PKB and Pyk-2 in VSMC [17,18]. In addition, we have also demonstrated that 
Ca2+ and Calmodulin (CaM) play an important role in mediating H2O2-induced ERK1/2 
and PKB phosphorylation in VSMC [13]. CaMKII is a multifunctional serine/threonine 
protein kinase which is believed to transduce the downstream effects of Ca2+/CaM [19]. 
CaMKII holoenzyme is a multimeric protein which contains 12 subunits arranged in two 
sets of six subunits that form a stacked hexagonally shaped rings [19]. Each subunit of 
CaMKII  contains three main regions: a N-terminal catalytic region responsible for 
catalyzing the phosphotransferase  reaction, a regulatory region that contains Ca2+/CaM 
binding sites and autoinhibitory domain (AID) and the C-terminal subunit association 
region responsible for assembling the multimeric holoenzyme [19]. In the absence of 
bound Ca2+/CaM, the CaMKII is maintained in an inactive state because of an interaction 
of the AID with the catalytic domain of its own subunit [20]. The Ca2+/CaM complex 
binds to a sequence that overlaps the AID and causes a conformational change, thereby 
relieving the inhibitory effect of AID on the catalytic activity and inducing the 
phosphorylation of the CaMKII in thr286 and enhancing its kinase activity [19] 
AngII, which transduces its effect through ROS generation [21], has been shown to 
phosphorylate and activate CaMKII in VSMC, and AngII-induced activation of ERK1/2 
has been shown to be blocked by pharmacological inhibitor of CaMKII [22]. However, a 
role of CaMKII in mediating H2O2-induced phosphorylation of ERK1/2, PKB, Pyk2 and 
IGF-1R in VSMC remains unexplored. Therefore, in the present studies, by using a series 
of pharmacological inhibitors and molecular approaches, we have investigated the 
involvement of CaMKII and associated pathways in H2O2-induced phosphorylation of 
these signaling components in A-10 VSMC.  
 
 105
Materials and Methods 
Materials 
H2O2 , glucose and glucose oxidase were procured from Sigma (St. Louis, MO, USA). 
Calmidazolium, W-7, KN-93, KN-92 and CaMKII autoinhibitory domain (AID) specific 
peptide inhibitor (AA 281-309, autoinhibitory peptide (AIP)) were obtained from 
Calbiochem and Lipofectamine was form Invitrogen, Canada. Monoclonal phospho-
specific- Thr202 -Tyr204-ERK1/2 antibody, polyclonal ERK1/2 antibody, CaMKII  
siRNA (catalogue number sc-29901), control siRNA (catalogue number sc-37007), 
transfection reagent for siRNA (catalogue number sc-29528), phospho-specific-Thr286-
CaMKII, anti-CaMKII, anti-IGF-1R and -actin antibodies were from Santa Cruz 
Biotech (Santa Cruz, CA). CaMKII siRNA is a pool of 3 target-specific, 20-25 
nucleotide siRNAs designed to knock down gene expression of CaMKII. The non-
specific siRNA (scrambled) consist of non-targeting 21 nucleotides with no homology to 
rat genes. The phospho-specific-Ser473-PKB, total PKB, phospho-specific-Tyr402-Pyk2, 
total Pyk2 antibodies as well as horseradish peroxidase-conjugated anti-rabbit antibodies 
were procured from New England Biolabs (Beverly, MA). Anti-pIGF-1R was obtained 
from Biosource. The enhanced chemiluminescence (ECL) detection system kit was from 
Amersham Pharmacia Biotech (Baie d’Urfé, QC, Canada).  
Cell culture 
VSMC derived from embryonic rat thoracic aorta A-10 cells were maintained in culture 
with Dulbecco’s modified eagle medium (DMEM)containing 10% fetal bovine serum at 
370C in a humidified atmosphere of 5% CO2 as described earlier [23]. The cells were 
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grown to 80-90% confluence in 60-mm plates and incubated in serum-free DMEM 5h 
prior to the treatments. 
Transfection with CaMKII auto- inhibitory peptide 
A-10 VSMCs at 80-90 % confluence were transfected with a CaMKII-specific (281-309) 
auto-inhibitory peptide (AIP) (2ng/ml) by using lipofectamine (4μg/ml) [24]. 
Transfections were performed in serum and antibiotics-free DMEM for 2h then serum 
was added to reach a final concentration of 10%. H2O2-induced signaling responses in 
peptide-transfected or control cells were examined 48h later. 
Transfection with siRNA 
A-10 VSMCs at 80-90 % confluence were transfected with CaMKII siRNA or control 
scrambled siRNA (final concentration of CaMKII or scrambled, non-specific siRNA 
was 70 nM) according to the manufacturer’s protocol. Transfections were performed in 
serum and antibiotics-free DMEM. A mixture of CaMKII siRNA or control scrambled 
siRNA and transfection reagent was added to cells and incubated for 6h at 37oC then 
serum was added to reach 10% of FBS. Cells were incubated for an additional 48h before 
stimulation with H2O2 
Cell treatment, lysis and Immunoblotting 
A-10 VSMCs, made quiescent by serum deprivation for 5 h, were treated in the absence 
or presence of various agents (e.g. H2O2, W-7, calmidazolium, KN-93, AIP or siRNA) at 
37oC as indicated in the legends to each figure. None of these treatments altered the 
viability of cells. Following these treatments the cells were washed twice with ice-cold 
PBS and lysed in 200 μl of buffer (25 mM Tris-HCl, pH 7.5, 25 mM NaCl, 1 mM Na 
orthovanadate, 10 mM Na fluoride, 10 mM Na pyrophosphate, 2 mM benzamidine, 2 
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mM ethylenebis(oxyethylenenitrolo)-tetraacetic acid, 2 mM ethylenediamine tetraacetic 
acid, 1 mM phenylmethylsulfonyl fluoride, 10 μg/ml aprotinin, 1% Triton X-100, 0.1% 
sodium dodecyl sulfate (SDS), and 0.5 μg/ml leupeptin) on ice. The cell lysates were 
centrifuged at 12,000 g for 10 min at 40C. Protein concentrations were measured by 
Bradford assay. Equal amounts of protein were subjected to 7.5% SDS-polyacrylamide 
gel (SDS-PAGE), transferred to PVDF membranes (Millipore, MA, USA) and incubated 
with respective primary antibodies, (monoclonal phospho-specific- Thr202 -Tyr204-
ERK1/2 antibody (1:4,000), polyclonal phospho-specific-Ser473-PKB antibody, phospho-
specific-Tyr402-Pyk2 and phospho-specific-IGF-1R antibody (1:1,000). phospho-specific-
Thr286-CaMKII antibody (1:2,000). The antigen-antibody complex was detected by a 
horseradish peroxidase-conjugated second antibody (1:2000), and protein bands were 
visualized by ECL. The intensity of specific bands was quantified by NIH Image 
software as described previously [25]. 
Statistics 
The data are means ± SE of at least three individual experiments. Statistical significance 
was determined with paired or unpaired Student’s t test, and p<0.05 was considered 
significant. 
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Results 
Pharmacological inhibitors of CaM abolish H2O2-induced ERK1/2 and PKB 
phosphorylation in A-10 VSMCs. We have reported earlier that Ca2+-dependent events 
are essential to tranduce the signals of H2O2 to enhance the phosphorylation of ERK1/2 
and PKB in A-10 VSMC [13]. Since CaM mediates various actions of Ca2+, we examined 
the involvement of CaM in H2O2-induced ERK1/2 and PKB phosphorylation. As shown 
in Fig.1, pretreatment of A-10 VSMCs with W-7 and calmidazolium, specific inhibitors 
of CaM, dose-dependently attenuated H2O2-induced phosphorylation of both ERK1/2 and 
PKB. However, as compared to ERK1/2, PKB appeared to be more sensitive to the 
inhibitory effect of both W-7 and calmidazolium, and exhibited almost complete 
attenuation of H2O2-stimulated phosphorylation of PKB at 5 μM of W-7 and 10 μM of 
calmidazolium (Fig.1 A and C). In contrast, a higher concentration of these inhibitors was 
required to attain the same level of inhibition of H2O2-enhanced phosphorylation of 
ERK1/2 (Fig.1, B and D).
CaMKII inhibitor attenuates H2O2 -induced ERK1/2 and PKB phosphorylation in A-10 
VSMC. CaMKII is a downstream signaling molecule that participates in mediating the 
effects of CaM [19]. Therefore, we examined whether CaMKII mediates the effect of 
H2O2 in enhancing the phosphorylation of ERK1/2 and PKB in A-10 VSMC. As shown 
in Fig.2, pretreatment of VSMC with KN-93, a specific CaMKII inhibitor which inhibits 
CaMKII by competitively binding to the CaM binding domain of the enzyme, dose-
dependently blocked the stimulatory effect of H2O2 on both ERK1/2 and PKB 
phosphorylation. 
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Calmodulin and CaMKII inhibitors attenuate glucose/glucose oxidase -induced 
ERK1/2 and PKB phosphorylation in A-10 VSMC. In order to investigate if 
endogenously generated H2O2 would exert a similar effect on ERK1/2 and PKB 
phosphorylation in A-10 VSMC as was observed with the exogenously added H2O2, we 
examined the effect of glucose (G) and glucose oxidase (GO), known to generate H2O2 
extracellulary [26], on ERK1/2 and PKB phosphorylation in these cells. As shown in 
Fig.3 A and B, G/GO treatment dose-dependently enhanced the phosphorylation of both 
ERK1/2 and PKB. However, as compared to PKB, G/GO caused a more potent 
phosphorylation of ERK1/2. Time course of G/GO response using 0.64 U/ml GO 
revealed that phosphorylation of both ERK1/2 and PKB by G/GO treatment was rapid 
(Fig.3 C and D) and was detectable at 5min. However, as compared to the 
phosphorylation of ERK1/2 which remained elevated during the 30 min of treatment 
(Fig.3D), PKB phosphorylation was transient and was decreased to the basal levels 
within 15 min of treatment (Fig.3C).  
Next, we determined whether similar to exogenously H2O2, pharmacological blockade of 
CaM or CaMKII will exert an inhibitory effect on G/GO-induced phosphorylation of 
ERK1/2 and PKB. As shown in Fig.4, pretreatment of cells with either calmidazolium or 
KN-93 prior to the addition of G/GO significantly inhibited G/GO-evoked 
phosphorylation of both PKB (Fig.4A) and ERK1/2 (Fig.4B). 
 
CaMKII inhibitory peptide (AIP) and CaMKII siRNA attenuates H2O2 -induced 
ERK1/2 and PKB phosphorylation. In addition to the use of classical pharmacological 
inhibitors of CaM and CaMKII, we also confirmed the involvement of CaMKII in 
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mediating H2O2 responses by two additional approaches. In approach one, we utilized a 
peptide (AIP) corresponding to the AID of CaMKII (AA 281-309). As shown in Fig.5 
transfection of A-10 VSMC for 48-h with AIP, markedly reduced H2O2-induced 
phosphorylation of both ERK1/2 and PKB (Fig.5). Lipofectamin, the transfection 
reagent, had no effect on H2O2-induced ERK1/2 and PKB phosphorylation (Fig.5). In the 
second approach, CaMKII expression was suppressed by siRNA-induced knock down 
of CaMKII . As shown in Fig. 6A, siRNA-induced knock-down of CaMKII decreased 
the expression of CaMKII by about 90% but had no effect on the expression of -actin. 
The cells treated with siRNA to CaMKII exhibited a significantly attenuated effect of 
H2O2 on the phosphorylation of both PKB and ERK1/2 (Fig. 6B and C respectively). 
However, control siRNA was without any effect on CaMKII expression (Fig.6 A) or on 
H2O2-induced ERK1/2 and PKB phosphorylation (Fig.6 B,C)  
H2O2 induces CaMKII phosphorylation in A-10 VSMC. Since Thr286 phosphorylation is 
critical for the activation of CaMKII activity, therefore, we wished to determine the effect 
of H2O2 on CaMKII phosphorylation in A-10 VSMC. To determine the effect of H2O2 on 
Thr286 autophosphorylation, A-10 VSMC were treated for different time periods with 
H2O2 and the lysates were immunoblotted with a specific antibody that recognizes 
CaMKII phosphorylation on Thr286. As shown in Fig.7A, H2O2 -induced the 
phosphorylation of CaMKII in a time-dependent fashion which peaked within 2 min of 
exposure with H2O2 and then declined to basal values at 10 min. Furthermore, both 
calmidazolium and KN-93 inhibited the phosphorylation of CaMKII induced by H2O2, 
whereas KN-92, an inactive analog of KN-93 was without any effect (Fig.7B) . 
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Calmidazolium and KN-93 blocked H2O2-induced phosphorylation of Pyk-2. We have 
demonstrated that Pyk-2, a non-receptor Ca2+-dependent proline rich tyrosine kinase is 
phosphorylated in response to H2O2    in A-10 VSMC [17]. A potential role of Pyk-2 in 
AngII-induced PKB signaling has been suggested [27]. Therefore, we investigated the 
effect of pharmacological blockade of CaM or CaMKII on H2O2- induced 
phosphorylation of Pyk-2. As shown in Fig.8 both calmidazolium and KN-93 prevented 
the phosphorylation of Pyk-2 induced by H2O2.  In contrast, KN-92  was without effect on 
H2O2-induced response. 
Calmidazolium, KN-93 and CaMKII siRNA  blocked H2O2-induced phosphorylation 
of IGF-1R. We have previously demonstrated that H2O2-induced the tyrosine 
phosphorylation of the subunit of IGF-1R and pharmacological blockade of the 
tyrosine kinase activity of IGF-1R inhibited H2O2-stimulted phosphorylation of ERK1/2, 
PKB and Pyk-2 in A10 VSMC [17,18]. Therefore, we examined the effect of CaM or 
CaMKII blockade on H2O2–induced tyrosine phosphorylation of IGF-1R. As shown in 
Fig.9,A,C,D both calmidazolium and KN-93 significantly reduced H2O2-stimulated 
phosphorylation of IGF-1R. Similarly, siRNA-induced suppression of CaMKII also 
exerted an inhibitory effect on the H2O2-evoked IGF-1R phosphorylation (Fig.9, B). 
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Discussion 
H2O2 has been shown to increase the intracellular Ca2+ concentration [28] and  we have 
reported in earlier studies that both Ca2+ and  CaM play a critical role in transducing 
H2O2-induced signaling events in VSMC [13]. In the studies presented here, we 
demonstrated that activation of CaMKII, a downstream effector of Ca2+/CaM responses, 
is required to enhance H2O2-induced phosphorylation of ERK1/2 and PKB. This 
conclusion is based on the use of highly selective pharmacological inhibitors of CaM and 
CaMKII. We have also confirmed the participation of CaMKII in mediating the H2O2-
induced phosphorylation of ERK1/2 and PKB by using siRNA to specifically knock 
down CaMKII  
Although, the involvement of CaMKII in H2O2-induced responses on NF-kappaB 
activation in T-lymphocytes [29], on ERK1/2 and p38MAPK activation and in eNOS 
expression in endothelial cells  [24,30], and on JNK and p38MAPK activation  in VSMC 
[31], have been demonstrated , to our knowledge, the data presented here are the first to 
show a role of CaMKII in mediating the effect of H2O2 on ERK1/2 and PKB 
phosphorylation in A10 VSMC. 
In addition to H2O2   other agonists such as AngII, norepinephrine, epidermal growth 
factor, ionomycin  and ATP have also been shown to activate MAPK signaling via 
CaMKII [22,32]. Our findings showing that H2O2 enhanced the phosphorylation of 
CaMKII in Thr286, further supports a role of activated CaMKII in H2O2-induced 
responses in VSMC. These data are also consistent with H2O2–induced increase in the 
phosphorylation of CaMKII reported in astrocytes  [33] and T-Jurkat-lymphocytes [34]. 
In contrast, our results do not support the observation of Robison et al, who showed a 
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decrease in CaMKII activity in response to H2O2 in neurons [35]. It should be noted that 
in addition to CaMKII, other receptor and non-receptor tyrosine kinase such as IGF-1R 
and Pyk-2  have been implicated in H2O2-induced signaling events in VSMC [17,36,37]. 
Our earlier studies have demonstrated that H2O2 enhanced the tyrosine phosphorylation of 
IGF-1R subunit  and this event contributed to the initiation of H2O2-evoked PKB 
phosphorylation with an intermediary role of Pyk-2 [17]. It has been shown that 
phosphorylated form of  Pyk-2 interacts with several signaling molecules such as Shc and 
Grb2 implicated in ERK1/2 activation, and with p85 subunit of phosphatidyl inositol 3-
kinase which is involved in PKB activation  [38]. Pyk-2 also mediates the effect of AngII 
in inducing ERK1/2 and PKB activation in VSMC [27]. Since ROS generation is critical 
in transducing AngII response, it is possible that Pyk-2 plays a similar role in H2O2-
induced effects on ERK1/2 and PKB phosphorylation. Our findings that inhibition of 
either CaM or CaMKII significantly attenuated H2O2-induced phosphorylation of Pyk-2 
indicates a requirement of CaMKII in enhancing Pyk-2 phosphorylation and suggest the 
participation of Pyk-2 in the signaling cascade leading to the activation of ERK1/2 and 
PKB in response to H2O2 in VSMC. The results showing that blockade of CaMKII 
either by pharmacological approach or by siRNA-induced silencing of CaMKII 
inhibited H2O2–induced tyrosine phosphorylation of IGF-1R, suggests an upstream role 
of CaMKII in this process. Although ionomycin-induced increase in EGF-R 
phosphorylation had earlier been shown to be mediated through CaMKII-dependent 
pathway [32], our current studies are the first to report that CaMKII plays a key  role in 
mediating H2O2-induced phosphorylation of IGF-1R, Pyk-2,  ERK1/2 and PKB. 
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An  involvement of CaMKII in regulating the proliferation, migration and differentiation 
of VSMC has been shown in several studies [39-43]. Since a hightened proliferation and 
migration of VSMC are hallmarks of vascular disease, and excessive generation of ROS 
has been suggested to play an important role in the pathogenesis of vascular diseases [5-
7,11] it may be suggested that ROS-induced upregulation of  CaMKII, through IGF-1R, 
ERK1/2 and PKB signaling pathways may contribute to aberrant VSMC functions 
associated with these disorders.  This notion is further supported by studies showing that 
pharmacological blockade of CaMKII by KN-93 improved vascular hyperplasia and 
hypertension in AngII-induced hypertensive rats [44], and normalized aberrant vascular 
reactivity in diabetes-induced vascular dysfunction [45]. 
In conclusion, we have shown that CaMKII serves as a critical upstream component in 
triggering the H2O2-induced signaling cascade resulting in the phosphorylation of IGF-
1R, ERK1/2 and PKB in VSMC. It may be suggested that through the activation of these 
signaling events CaMKII contributes to the regulation of various cellular processes 
including cell growth, proliferation, hypertrophy and survival in VSMC, and a 
dysregulation of CaMKII activity may play an important role in the pathogenesis of 
vascular disease. 
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Figures legends  
Figure 1.  Pharmacological inhibition of CaM abolishes H2O2-induced ERK1/2 and PKB 
phosphorylation in A-10 VSMCs. Serum-starved quiescent A-10 cells were pretreated in 
the absence (0) or presence of the indicated concentration of W-7 (section A and B) or 
calmidazolium (section C and D) for 30 min followed by stimulation with 250 μM of 
H2O2 for 5 min. Cell lysates were immunoblotted with phospho-specific-Ser473-PKB 
antibodies (A and C) and phospho-specific-Thr 202-Tyr204-ERK1/2 antibodies (B and D), 
as shown in the middle panels of each section. Blots were also analyzed for total ERK1/2 
and PKB (bottom panels of each section). Top panels (bar diagrams) in each section 
represent average data quantified by densitometric scanning of immunoblots showing in 
the middle panel. Values are the means  SE of at least 3 independent experiments and 
are expressed as percentage of control, taken as 100%. P< 0.05 considered as statistically 
significance versus H2O2 stimulation alone. 
* indicates that P < 0.05, ** indicates that P <0.005, and # indicates that P <0.0005.   
Figure 2. CaMKII inhibitor attenuates H2O2-induced ERK1/2 and PKB phosphorylation 
in A-10 VSMCs. Serum-starved quiescent A-10 cells were pretreated in the absence (0) 
or presence of the indicated KN-93 concentrations for 30 min followed by stimulation 
with 250 μM of H2O2 for 5 min. Cell lysates were immunoblotted with phospho-specific-
Ser473-PKB antibodies (A) and phospho-specific- Thr202 -Tyr204-ERK1/2 antibodies (B), 
as shown in the middle panels of each section. Blots were also analyzed for total ERK1/2 
and PKB (bottom panels of each section). Top panels (bar diagrams) in each section 
represent average data quantified by densitometric scanning of immunoblots showing in 
the middle panel. Values are the means  SE of at least 3 independent experiments and 
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are expressed as percentage of control, taken as 100%. P< 0.05 considered as statistically 
significance versus H2O2 stimulation alone. * indicates that P < 0.05, ** indicates that P 
<0.005 and # indicates that P <0.0005.   
Figure 3: Dose response and time course of glucose/glucose oxidase-induced ERK1/2 
and PKB phosphorylation in A-10 VSMCs. Serum-starved quiescent A-10 cells were 
treated without (0) or with 6mM glucose (G) and the indicated concentrations of glucose 
oxidase (GO) for 10 min (A and B) and without (0) or with G/GO (6mM/0.64 U/ml) for 
the indicated time periods (C and D). Cell lysates were immunoblotted with phospho-
specific-Ser473-PKB antibodies (A and C) and phospho-specific-Thr 202-Tyr204-ERK1/2 
antibodies (B and D), as shown in the middle panels of each section. Blots were also 
analyzed for total ERK1/2 and PKB (bottom panels of each section). Top panels (bar 
diagrams) in each section represent average data quantified by densitometric scanning of 
immunoblots shown in the middle panel. Values are the means  SE of at least 3 
independent experiments and are expressed as percentage of control, taken as 100%. P< 
0.05 considered as statistically significance versus control. 
* indicates that P < 0.05, ** indicates that P <0.005, and # indicates that P <0.0005.   
Figure. 4. Calmodulin and CaMKII inhibition blocks ERK1/2 and PKB phosphorylation 
induced by G/GO. 
Serum-starved quiescent A-10 cells were pretreated in the absence (0) or presence of 
CMZ, KN-92 or KN-93 (10 M) for 30 min followed by stimulation  with G/GO 
(6mM/0.64U/ml) for 10 min. Cell lysates were immunoblotted with phospho-specific-
Ser473-PKB antibodies (A) and phospho-specific-Thr 202-Tyr204-ERK1/2 antibodies (B), 
as shown in the middle panels of each section. Blots were also analyzed for total ERK1/2 
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and PKB (bottom panels of each section). Top panels (bar diagrams) in each section 
represent average data quantified by densitometric scanning of immunoblots shown in the 
middle panel. Values are the means  SE of at least 3 independent experiments and are 
expressed as percentage of control, taken as 100%. P< 0.05 considered as statistically 
significance versus G/GO stimulation. 
* indicates that P < 0.05, ** indicates that P <0.005, and # indicates that P <0.0005.   
Figure 5. CaMKII AIP peptide (AA 281-309) attenuates H2O2-induced ERK1/2 and PKB 
phosphorylation in A-10 VSMCs. Cells were transfected, using lipofectamin, with 
CaMKII autoinhibitory peptide (AIP) for 48-h prior to stimulation with H2O2  (250 μM, 
5min). The cells treated with lipofectamin alone were used as control. Cell lysates were 
immunoblotted with phospho-specific-Ser473-PKB antibodies (A) and phospho-specific-
Thr 202-Tyr204ERK1/2 antibodies (B), as shown in the middle panels of each section. 
Blots were also analyzed for total ERK1/2 and PKB (Bottom panels of each section). Top 
panels (bar diagrams) in each section represent average data quantified by densitometric 
scanning of immunoblots showing in the middle panel. Values are the means  SE of at 
least 3 independent experiments and are expressed as percentage of control, taken as 
100%. P< 0.05 considered as statistically significance versus H2O2 stimulation alone. # 
indicates that P < 0.0005.  
Figure 6.  CaMKII siRNA attenuates H2O2-induced ERK1/2 and PKB phosphorylation 
in A-10 VSMCs. A-10 VSMC were transfected with CaMKII siRNA or control siRNA 
for 48h prior to stimulation with H2O2 (250 μM, 5min). Cell lysates were immunoblotted 
with CaMKII antibodies (A), phospho-specific-Ser473-PKB antibodies (B) and phospho-
specific-Thr202-Tyr204-ERK1/2 antibodies (C). Blots were also analyzed for total PKB 
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and ERK1/2 (Bottom panels of B and C). Top panels (bar diagrams) in B and C represent 
average data quantified by densitometric scanning of immunoblots of p-Proteins showing 
in the middle panel. Blots in panel A was also blotted with  actin. Values are the means 
 SE of at least 3 independent experiments and are expressed as percentage of control, 
taken as 100%.  P< 0.05 considered as statistically significance versus H2O2 stimulation 
alone. ** indicates that P < 0.005 and # indicates that P < 0.0005. 
Figure.7. H2O2 induces the phosphorylation of CaMKII which is blocked by CaM and 
CaMKII inhibitors  in A-10 VSMC.  
(A): Serum-starved quiescent A-10 cells were treated with H2O2 (250 μM) for indicated 
time periods. (B): Quiescent A-10 cells were pretreated in the absence (0) or presence of 
calmidazolium(CMZ), KN-92 or KN-93 (10M) for 30 min followed by stimulation with 
250 μM of H2O2 for 5 min. Cell lysates were immunoblotted with phospho-specific-
Thr286-CaMKII antibodies (middle panel in each section) and total CaMKII antibodies 
(Bottom panel in each section). Top panels in each section (bar diagrams) represent 
average data quantified by densitometric scanning of immunoblots of p-CaMKII. Values 
are the means  SE of at least 3 independent experiments are expressed as percentage of 
control, taken as 100%. P< 0.05 considered as statistically significance versus control for 
(A) and versus H2O2 stimulation alone for (B). * indicates that P < 0.05, ** indicates that
P <0.005 and # indicates that P <0.0005.   
Figure.8. CaMKII inhibition blockes Pyk-2 phosphorylation induced by H2O2
Serum-starved quiescent A-10 cells were pretreated in the absence (0) or presence of 
CMZ, KN-92 or KN-93 (10M) for 30 min followed by stimulation with 250 μM of 
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H2O2 for 5 min. Cell lysates were immunoblotted with phospho-Pyk-2 antibodies (middle 
panel ) and total Pyk-2 antibodies (Bottom panel). Top panels in each section (bar 
diagrams) represent average data quantified by densitometric scanning of immunoblots of 
p-Pyk-2.  Values are the means  SE of at least 3 independent experiments are expressed 
as percentage of control, taken as 100%. P< 0.05 considered as statistically significance 
versus H2O2 stimulation alone. * indicates that P < 0.05, ** indicates that P <0.005. 
Figure. 9. CaMKII inhibition attenuates IGF-1R phosphorylation induced by H2O2
Serum-starved quiescent A-10 cells were pretreated in the absence (0) or presence of 
CMZ, KN-92 or KN-93 (10M) for 30 min followed by stimulation with 250 M of 
H2O2 for 5 min (A). In (B), A-10 VSMCs were transfected with either control siRNA or 
CaMKII  siRNA, as described in the legend to Fig 4, 48-h prior to stimulation with 250 
μM of H2O2 for 5 min.  In (C) and (D): Quiescent A-10 VSMC were pretreated with the 
indicated concentrations of CMZ (C) and KN-93 (D) for 30 min followed by stimulation 
with 250 μM of H2O2 for 5 min. Cell lysates were immunoblotted with p-IGF-1R 
antibodies that recognize the phosphorylated form of IGF-1R (phospho-Tyr1131/1135/1136) 
(middle panel in each section) and total IGF-R antibodies (Bottom panel in each section). 
Top panels in each section (bar diagrams) represent average data quantified by 
densitometric scanning of immunoblots of p-IGF-1R. Values are the means  SE of at 
least 3 independent experiments are expressed as percentage of control, taken as 100%. 
P< 0.05 considered as statistically significance versus H2O2 stimulation alone. * indicates 
that P < 0.05, ** indicates that P <0.005. 
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Abstract  
Nitric oxide (NO), in addition to its vasodilator action, has also been shown to 
antagonize the mitogenic and hypertrophic responses of growth factors and 
vasoactive peptides such as endothelin-1 (ET-1) in vascular smooth muscle cells 
(VSMCs). However, the mechanism by which NO exerts its anti-mitogenic and 
anti-hypertrophic effect remains unknown. Therefore, the aim of this study was 
to determine if NO generation would modify ET-1-induced signaling pathways 
involved in cellular growth, proliferation and hypertrophy in A-10 VSMC. 
Treatment of A-10 VSMCs with S-nitroso-N-acetylpenicillamine (SNAP) or 
sodium nitroprusside (SNP), two NO donors, attenuated the ET-1-enhanced 
phosphorylation of several key components of growth promoting and 
hypertrophic signaling pathways such as ERK1/2, PKB and Pyk2. On the other 
hand, the inhibition of the endogenous NO generation by using N-nitro-L- 
arginine methyl ester (L-NAME), a NO synthase inhibitor, increased the ET-1-
induced phophosphorylation of these signaling components. Since, NO 
mediates its effect principally through a cyclic GMP/soluble guanylyl cyclase 
(sGC) pathway, we investigated the role of these molecules in NO action. 8-Br-
cGMP, a non-metabolizable and cell permeable analogue of cGMP, exhibited a 
similar effect to that of SNAP and SNP. Furthermore, oxadiazole quinoxalin 
(ODQ), an inhibitor of sGC, reversed the inhibitory effect of NO on ET-1-
induced responses. SNAP treatment also decreased the protein synthesis 
induced by ET-1. Taken together, these data demonstrate that NO, in a cGMP-
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dependent manner, attenuated ET-1-induced phosphorylation of ERK1/2, PKB 
and Pyk2 and also antagonized the hypertrophic effects of ET-1. It may be 
suggested that NO-induced generation of cGMP contributes to the inhibition of 
ET-1-induced mitogenic and hypertrophic responses in VSMCs. (260words) 
Key words:  Cell signaling, protein synthesis, endothelin-1, NO.  
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Introduction 
 Endothelin-1 (ET-1) is a 21-amino acid peptide and is considered as a 
potent vasoconstrictor (47). It also exhibits mitogenic activity in vascular 
smooth muscle cells (VSMC) (5; 23; 24), suggesting a possible role for ET-1 in 
the pathogenesis of many diseases, such as atherosclerosis (29), hypertension 
(18) and restenosis after angioplasty (11). 
 ET-1 exerts its effects through heteromeric G-protein-coupled receptor 
(GPCR) that is linked to multiple signaling pathways which include 
phospholipases C and D (13), Ca2+ (32), mitogen-activated protein kinases 
(MAPKs) including extracellular signal-regulated kinases 1/2 (ERK1/2), c-Jun-
NH2-terminal kinase (JNK) and p38mapk (7; 8; 39; 50; 51) and 
phosphatidylinositol 3-kinase (PI-3K) (8; 17). Activation of receptor and non-
receptor protein tyrosine kinases (PTKs) in transducing ET-1-induced signaling 
responses have also been suggested (16; 26; 27; 39; 49). PTKs activated by ET-
1 include epidermal growth factor (EGF) (27), c-Src (16; 26; 38) and a Ca2+-
dependent PTK, Pyk2 (26; 39). Of particular interest, ET-1 mediates Pyk2 
activation which contributes to ERK1/2 (26) and JNK (27) signaling in 
cardiomyocytes and p38mapk (39) in mesangial cells. 
 
 Nitric oxide (NO) is a free radical that has been suggested to play  an 
important role in cardiovascular function (38). NO mediates relaxation principally 
through the stimulation of soluble guanylyl cyclase (sGC), leading to enhanced 
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production of intracellular cGMP, which in turn, activates cGMP-dependent 
protein kinases (PKG) (30). NO can also influence cellular events by a PKG-
independent mechanism (14; 22), and is also able to react with superoxide anion 
to form the reactive peroxynitrite radical (25), a potent oxidant with the potential 
to disrupt protein structures by nitrating the tyrosine residues in protein (48). In 
addition to its vasodilating effect, NO has been suggested to antagonize the 
physiological and pathophysiological effects of several growth factors such as 
EGF (52), angiotensin II (AII) (46) as well as ET-1 (1). This is probably achieved 
by inhibiting one or more serine/ threonine/ tyrosine kinases implicated in the 
signaling events induced by these factors. Several studies using AII, have shown 
that NO suppressed the activation of ERK1/2, p38mapk and JNK (45) as well as 
Pyk2 (46) in cardiac fibroblasts. It has also been recently reported that in rat 
neonatal pulmonary vascular smooth muscle cells a NO donor inhibited ET-1-
induced ERK1/2 phosphorylation (3). However, to our knowledge, a possible 
contribution of NO on ET-1-induced activation of other signaling events has not 
been investigated in VSMC. Therefore, in the present studies, we have examined 
the effect of NO on ET-1-stimulated phosphorylation of ERK1/2, PKB and Pyk2, 
the key mediators of growth-promoting, proliferative, hyperthrophic survival 
responses. In addition, we have also examined whether NO acts via a cGMP-
dependent mechanism in eliciting these responses.  
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Materials and Methods 
Materials
ET-1 was purchased from Peninsula Laboratories (Belmont, CA, USA), 
and S-nitroso-N-acetylpenicillamine (SNAP), sodium nitroprusside (SNP), 8-
Bromo-guanosine 3’, 5’-cyclic monophosphate (8-Br-cGMP) and 1H-
1,2,4Oxadiazolo4,3-aquinoxalin-1-one (ODQ), were obtained from 
Calbiochem (San Diego, CA). L-NAME was purchased form Sigma Aldrich (St-
Louis, MO). Monoclonal phospho-specific-Tyr204-ERK1/2 antibody, polyclonal 
ERK1/2 antibody, eNOS antibody, iNOS antibody and horseradish peroxidase-
conjugated goat anti-mouse immunoglobulin were from Santa Cruz Biotech 
(Santa Cruz, CA). The phospho-specific-Ser473-PKB and total PKB as well as 
phospho-specific-Tyr402-Pyk2 and total Pyk2 antibodies were procured from 
New England Biolabs (Beverly, MA). The enhanced chemiluminescence (ECL) 
detection system kit and L-(4,5-3H) leucine were from Amersham Pharmacia 
Biotech (Baie d’Urfé, QC, Canada). Human umbilical vein endothelial cells 
(HUVEC) was a gift from Dr  Eric Thorin, Montreal Cardiology Institute. 
 
Methods
Cell culture 
A-10 VSMC derived from embryonic rat thoracic aorta cells were 
maintained in culture with DMEM containing 10% fetal bovine serum at 370C in 
a humidified atmosphere of 5% CO2 as described earlier (40). The cells were 
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grown to 80-90% confluence in 60-mm plates and incubated in serum-free 
DMEM 20 h prior to the treatments. 
Cell lysis and Immunoblotting 
Cells incubated in the absence or presence of various agents were washed 
twice with ice-cold PBS and lysed in 200 l of buffer (25 mM Tris-HCl, pH 7.5, 
25 mM NaCl, 1 mM Na orthovanadate, 10 mM Na fluoride, 10 mM Na 
pyrophosphate, 2 mM benzamidine, 2 mM ethylenebis(oxyethylenenitrolo)-
tetraacetic acid, 2 mM ethylenediamine tetraacetic acid, 1 mM 
phenylmethylsulfonyl fluoride, 10 g/ml aprotinin, 1% Triton X-100, 0.1% 
sodium dodecyl sulfate (SDS), and 0.5 g/ml leupeptin) on ice. The cell lysates 
were centrifuged at 12,000g for 10 min at 40C. Protein concentrations were 
measured by Bradford assay. Equal amounts of protein were subjected to either 
7.5% or 10% SDS-polyacrylamide gel (SDS-PAGE), transferred to PVDF 
membranes (Millipore, MA, USA) and incubated with respective primary 
antibodies, (monoclonal phospho-specific-Tyr204-ERK1/2 antibody (1:2,000), 
polyclonal phospho-specific-Ser473-PKB antibody (1:4,000), phospho-specific-
Tyr402-Pyk2 antibody (1:1,000), eNOS or iNOS antibodies (1:2,000)). The 
antigen-antibody complex was detected by a horseradish peroxidase-conjugated 
second antibody (1:4000), and protein bands were visualized by ECL. The 
intensity of specific bands was quantified by NIH Image software as described 
previously (31). 
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Measurement of [3H]leucine Incorporation 
A-10 cells were treated for 20 h with endothelin-1 (10 nM; Belmont, CA, 
USA). Protein synthesis was assessed by the addition of 2 Ci/mL of 
3H]leucine (ICN Biomedicals, Inc., Costa Mesa, CA, USA) for a period of 20 h. 
To assess the role of NO, cells were pretreated for 30 min with 10 or 100 μM of 
S-nitroso-N-acetylpenicillamine (SNAP) (Calbiochem, San Diego, CA) which 
spontaneously generates NO. Following the completion of the experimental 
protocol, A-10 cells were washed twice with cold PBS, and 1 ml of cold 5% 
trichloroacetic acid was added for 30 min to precipitate protein. The precipitates 
were subsequently washed twice with cold water and resuspended in 500 l of 
0.4 M NaOH. Aliquots were counted in a scintillation counter. 
              Statistics 
Statistical analysis was performed by one-way, repeated-measures analysis 
of variance (ANOVA) followed by a Fisher post hoc test. All data are reported 
as means + SE. The differences between means were considered significant at 
P 0.05. 
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Results 
 
Both SNAP and SNP inhibited ET-1-induced phosphorylation of ERK1/2, 
PKB and Pyk2  in A-10 VSMCs 
In order to determine if the anti-mitogenic and anti-proliferative effects of 
NO are mediated by its ability to attenuate growth-promoting signaling pathway 
in VSMC, we examined the effect of S-nitroso-N-acetylpenicillamine (SNAP), 
which spontaneously generates NO, on ET-1-induced phosphorylation of 
ERK1/2, PKB and Pyk2. As shown in Fig. 1, pretreatment of A-10 VSMC with 
SNAP for 15 min dose-dependently attenuated ET-1-induced phosphorylation of 
all of these protein kinases. Among the kinases, PKB appeared to be more 
sensitive to the inhibitory effect of SNAP and exhibited almost complete 
attenuation of ET-1-stimulated phosphorylation at 10 M (Fig. 1B). In contrast, 
ET-1-enhanced phosphorylation of ERK1/2 and Pyk2 was inhibited significantly 
only at 300 M SNAP.  
In addition, sodium nitroprusside (SNP), another NO donor also exhibited 
a similar effect and attenuated ET-1-induced ERK1/2, PKB and Pyk2 
phosphorylation to varying degrees (Fig. 2).    
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L-NAME potentiated ET-1-induced phosphorylation of ERK1/2, PKB and 
Pyk2  in A-10 VSMCs. 
 To  examine if decreasing the endogenous NO production by inhibition of 
nitric oxide synthase (NOS) activity would modify the effect of ET-1 on various 
signaling components, we investigated the effect of pretreatment of A-10 VSMC 
with L-NAME, a specific inhibitor of NOS on ET-1-induced phosphorylation of 
ERK1/2, PKB and Pyk2. As shown in Fig.3, L-NAME treatment, at both the 
doses used, potentiated the response of ET-1 on all three signaling component 
examined. 100 M L-NAME potentiated ET-1-induced ERK1/2 
phosphorylation by 4 fold (Fig. 3A), whereas only 2 fold potentiation in PKB 
and Pyk2 phosphorylation was observed under these conditions (Fig. 3B,C). 
Although, it is generally believed that VSMC are devoid of NOS, however, the 
ability of L-NAME to potentiate ET-1-induced signaling suggested the presence 
of NOS in A10-VSMC. This possibility was evaluated by subjecting the total 
cellular lysates of A10-VSMC or HUVEC to western blotting using specific 
antibodies against eNOS and iNOS. As shown in Fig.4A, A10 cells exhibited a 
significant expression of eNOS in the basal state. However, as compared to 
HUVEC the expression level of eNOS in A10-VSMC  was much less. Under 
these conditions iNOS could not be detected in A10-VSMC (data not shown). 
Furthermore, treatment of A10-VSMC with ET-1 or L-NAME did not alter the 
eNOS expression in these cells (Fig.4B)                   
8-Br-cGMP inhibited ET-1-induced phosphorylation of ERK1/2, PKB and 
Pyk2  in A-10 VSMCs 
 
 147
Since SNAP-induced production of NO would cause an elevation in 
cGMP, we evaluated the possibility that the effect of SNAP on ET-1-induced 
responses was mediated by a mechanism involving cGMP. We tested this by 
pretreating the cells with 8-Br-cGMP, a non-metabolizable and cell permeable 
analogue of cGMP. As shown in Fig.5, treatment of cells with 8-Br-cGMP 
decreased ET-1-induced ERK1/2, PKB and Pyk2 phosphorylation. 100 M 8-
Br-cGMP inhibited ET-1-induced ERK1/2 and Pyk2 phosphorylation almost 
completely , whereas,  50% inhibition  in PKB phosphorylation was observed. 
ODQ reversed the inhibitory effect of SNAP on ET-1-induced ERK1/2, PKB 
and Pyk2 in A-10 VSMCs 
Since NO stimulates cGMP production by activating a soluble form of 
guanylate cyclase, we wished to determine the contribution of this enzyme in 
SNAP-induced attenuation of ET-1 response. To validate this possibility, we 
used ODQ, a selective inhibitor of the soluble guanylate cyclase (sGC), which 
prevents the generation of cGMP from GTP. For these experiments, cells were 
preincubated with ODQ for 15 min, then with 300 M SNAP for 15 min and 
finally stimulated with 10 nM ET-1 for 5 min. As shown in Fig. 6, A-C, 
pretreatment with 10 M ODQ resulted in a significant reversal in the inhibitory 
effect of SNAP on ET-1-stimulated ERK1/2, PKB and Pyk2 phosphorylation. 
Under these conditions however, pretreatment of cells with ODQ alone did not 
modify ET-1-induced ERK1/2, PKB and Pyk2 phosphorylation. (Fig.6D)  
 
 148
SNAP inhibited ET-1-stimulated [3H]leucine incorporation into proteins 
Activation of ERK1/2, PKB and Pyk2 signaling has been implicated in 
mediating the hypertrophic response of ET-1 (42). Therefore, we next examined 
whether there was a correlation between the response of SNAP and ET-1-
induced protein synthesis. As shown in Fig.7, ET-1 increased [3H]leucine 
incorporation in total cellular proteins by about 50% over control. However, 
pretreatment of cells with SNAP  dose-dependently decreased ET-1-induced 
[3H]leucine incorporation with almost complete attenuation observed at 100 M 
of SNAP. SNAP alone did not significantly affect basal [3H]leucine uptake. 
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Discussion 
  
Here we have provided evidence showing that NO generation induced by SNAP 
and SNP significantly attenuated  ET-1-enhanced phosphorylation of ERK1/2, 
PKB and Pyk2  in VSMC. We have also demonstrated that SNAP treatment was 
able to antagonize ET-1-induced total protein synthesis, an index of 
hypertrophy, in VSMC. Since both ERK1/2 and PKB pathways play critical 
role in mediating  hypertrophic and cell survival responses (8),  it is reasonable 
to suggest that the ability of NO donors to inhibit ET-1-induced activation of 
these pathways is responsible for the antihypertrophic and vascular protective 
effect of NO. Although NO donors have been found to attenuate EGF (52), 
Platelet-Derived Growth Factor (PDGF) (35) and AII (44) stimulated 
proliferation of VSMC and cardiac fibroblasts, studies reported here are the first 
to demonstrate an effect of NO on ET-1-induced phosphorylation of ERK1/2, 
PKB and Pyk2 in A-10 VSMC. These results are similar to the studies in 
neonatal pulmonary VSMC, in which SNP treatment was found to inhibit ET-1-
induced ERK1/2 phosphorylation (3) and in rat cardiac fibroblasts, where AII-
induced phosphorylation of ERK1/2 and Pyk2 was blocked by SNAP (45; 46). 
However, our work represents the first study demonstrating that NO 
antagonizes ET-1-induced PKB and Pyk2 activation as well as ET-1-induced 
protein synthesis in VSMC.   
 The demonstration that pharmacological inhibition of basal NO production 
by using L-NAME augmented ET-1 responses on ERK1/2, PKB and Pyk2 
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phosphorylation support an inhibitory role of NO on ET-1-induced signaling 
events in A10-VSMC. A similar increase in ET-1-induced phosphorylation of 
ERK1/2 in L-NAME treated pulmonary artery VSMC has also been 
demonstrated (3). It is generally believed that VSMC are devoid of NOS 
activity however, recently, both iNOS and eNOS immunoreactivity as well as 
NOS activities have been detected in isolated VSMC (9; 10; 34). Our results 
showing that A10-VSMC express eNOS in the basal state, further supports the 
presence of eNOS in VSMC. Thus it is possible that L-NAME-induced 
inhibition of eNOS by decreasing NO bioavailability potentiates ET-1-induced 
signaling events in these cells. 
NO is believed to exert its  physiological effect through activation of sGC, a 
heme containing protein (20). Binding of NO to the heme iron leads to allosteric 
modification of sGC, resulting in its enhanced catalytic activity to produce 
cGMP (21). cGMP, thus generated, elicits its downstream responses by 
interacting with its target proteins such as PKG (37). Additional non-
sGC/cGMP-dependent mechanism of NO action has also been suggested, which 
include ONOO- catalyzed post-translational modification of protein via 
nitration of tyrosine residues (6). However, our results showing that 8-Br-cGMP 
mimicked the effect of SNAP and SNP in decreasing ET-1-induced  ERK1/2, 
PKB and Pyk2 phosphorylation suggest that an intermediary role of cGMP in 
exerting this inhibitory response. Further proof for the involvement of sGC in 
this processes has been provided by using ODQ, a specific inhibitor of sGC 
which can block SNAP-induced elevations in cGMP levels in rat aortic VSMC 
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(28), A-10 VSMC (4), endothelial cells (19) and cardiomyocytes (36). We 
found that ODQ treatment of A-10 VSMC was able to significantly reverse the 
inhibitory effect of SNAP on ET-1-induced ERK1/2, PKB and Pyk2 
phosphorylation. A similar involvement of cGMP/PKG pathway in NO-induced 
inhibition of ERK1/2 phosphorylation by ET-1 in cardiomyocytes and in 
pulmonary artery VSMC has also been reported (3; 12). The fact that 8-Br-
cGMP caused only partial inhibition of ET-1-induced PKB phosphorylation and 
ODQ was not able to completely reverse the SNAP-induced responses in our 
studies suggest a partial contribution of non-cGMP-dependent events in 
mediating the effect of NO donors in ET-1-induced responses. These cGMP-
independent mechanisms include nitration of some upstream signaling 
components resulting in attenuation of their catalytic activity. Existence of 
cGMP-independent mechanism in mediating the antiproliferative effects of NO 
has also been suggested from other studies in which ODQ, despite lowering 
NO-induced cGMP levels, failed to reverse the antiproliferative effect of NO 
donors in pulmonary microvascular smooth muscle cells (41) or in human 
endothelial cells (19). In these studies , however the effect of ODQ on signaling 
pathways linked to proliferative responses was not investigated.        
 The precise mechanism by which cGMP inhibits ERK1/2 signaling 
remains elusive however, the ability of PKG, the downstream effector of cGMP 
action, to phosphorylate  c-Raf kinase on Ser 43 and the resulting uncoupling 
between Ras-Raf  might contribute to this effect (43). Since the upstream 
elements leading the PKB phosphorylation are different from that of ERK1/2 
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(8), the precise mechanism by which cGMP/PKG system attenuates PKB 
phosphorylation remain undefined.  
Pyk2 is a Ca2+ -dependent proline rich-non receptor protein tyrosine kinase 
which plays an essential role in Ang II-induced ERK1/2 signaling and 
hypertrophy in VSMC  (33)    Pyk2 is activated by autophosphorylation in 
Tyr402 located in its catalytic domain (2). It thus may also be possible that 
SNAP/cGMP-induced decrease in Pyk2 phosphorylation observed in our studies 
contributed to the attenuating effect of SNAP on ET-1-induced signaling in A-
10 VSMC. NO generation has been shown to attenuate IGF-1 and insulin-
induced elevation in H2O2 levels through a cGMP dependent event in VSMC 
(53). ET-1–induced ERK1/2 and PKB signaling is known to require activation 
of NADPH-oxidase system and resultant H2O2 generation (15). Thus, it is 
possible that a NO/cGMP induced reduction in H2O2 generation contributes to 
the decrease in ET-1 response observed in our studies.        
       
Taken together, we have demonstrated that SNAP and SNP, a NO 
donors, inhibit ET-1-stimulated increase of ERK1/2, PKB and Pyk2 
phosphorylation through a  cGMP/sGC-dependent mechanism in A-10 VSMC. 
We have also provided evidence showing that ET-1-stimulated protein 
synthesis, a hallmark of hypertrophic response, is also attenuated by NO donor 
SNAP in A-10 VSMC. Since ERK1/2, PKB and Pyk2 plays a crucial role in 
mediating VSMC growth and hypertrophy, it may be suggested that the ability 
of NO to attenuate these pathways may serve as a potential mechanism by 
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which NO counteracts the growth promoting and hypertrophic responses of ET-
1 in VSMC. 
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Figure legends  
Figure 1. Dose-dependent effect of the NO donor, SNAP on ET-1-induced 
ERK1/2, PKB and Pyk2 phosphorylation in A-10 VSMCs. Serum-starved 
quiescent A-10 cells were pretreated without or with the indicated SNAP 
concentrations for 15 min followed by 10 nM of ET-1 for 5 min. Cell lysates 
were immunoblotted by phospho-specific-Tyr204-ERK1/2 antibodies (A), 
phospho-specific-Ser473-PKB antibodies (B) and phospho-specific-Tyr402-Pyk2 
antibodies (C), as shown in the top panels of each section. Blots were also 
analyzed for total ERK1/2, PKB and Pyk2 (middle panels of each section). 
bottom panels, (bar diagrams) in each section represent average data quantified 
by densitometric scanning of immunoblots. Values are the means  SE of at 
least 3 independent experiments and are expressed as percentage 
phosphorylation where phosphorylation observed with ET-1 alone is defined as 
100%. (A) *P< 0.0001 vs control, †P< 0.0001 vs ET-1. (B) *P< 0.0001 vs 
control, †P< 0.0001 vs ET-1. (C) *P< 0.002 vs control, †P< 0.0003 vs ET-1. 
Figure 2. Dose-dependent effect of the NO donor, SNP on ET-1-induced 
ERK1/2, PKB and Pyk2 phosphorylation in A-10 VSMCs. Serum-starved 
quiescent A-10 cells were pretreated without or with the indicated SNP 
concentrations for 15 min followed by 10 nM of ET-1 for 5 min. Cell lysates 
were immunoblotted by phospho-specific-Tyr204-ERK1/2 antibodies (A), 
phospho-specific-Ser473-PKB antibodies (B) and phospho-specific-Tyr402-Pyk2 
antibodies (C), as shown in the top panels of each section. Blots were also 
analyzed for total ERK1/2, PKB and Pyk2 (middle panels of each section). 
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Bottom panels (bar diagrams) in each section represent average data quantified 
by densitometric scanning of immunoblots. Values are the means  SE of at 
least 3 independent experiments and are expressed as percentage 
phosphorylation where phosphorylation observed with ET-1 alone is defined as 
100%. (A) *P< 0.0003 vs control, †P< 0.0001 vs ET-1. (B) *P< 0.001 vs 
control, †P< 0.0006 vs ET-1. (C) *P< 0.0003 vs control, †P< 0.0002 vs ET-1. 
Figure 3. Effect of L-NAME, a NO synthase inhibitor,  on ET-1-induced 
ERK1/2, PKB and Pyk2 phosphorylation in A-10 VSMCs. Serum-starved 
quiescent A-10 cells were pretreated without or with the indicated L-NAME 
concentrations for 30 min followed by 10 nM of ET-1 for 5 min. Cell lysates 
were immunoblotted by phospho-specific-Tyr204-ERK1/2 antibodies (A) and 
phospho-specific-Ser473-PKB antibodies (B), and phospho-specific-Tyr402-Pyk2 
antibodies (C), as shown in the top panels of each section. Blots were also 
analyzed for total ERK1/2, PKB and Pyk2 (middle panels of each section). 
Bottom panels (bar diagrams) in each section represent average data quantified 
by densitometric scanning of immunoblots. Values are the means  SE of at 
least 3 independent experiments and are expressed as percentage 
phosphorylation where phosphorylation observed with ET-1 alone is defined as 
100%. (A)     *P< 0.003 vs control, †P< 0.005 vs ET-1. (B) *P< 0.0001 vs 
control, †P< 0.0003 vs ET-1. (C) *P< 0.0001 vs control, †P< 0.0005 vs ET-1. 
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Figure 4.  Expression of eNOS in A10-VSMC. Total cellular lysates from 
HUVEC (15g) or A10-VSMC (60g) were subjectd to SDS-PAGE followed 
by immunoblotting using eNOS antibody as described in the materials and 
methods (A); Serum-starved quiescent A-10 cells were pretreated without or 
with the indicated L-NAME concentrations for 30 min followed by 10 nM of 
ET-1 for 5 min. Cell lysates were immunoblotted by using eNOS specific 
antibody (B). 
Figure 5. Effect of a stable analogue of cGMP, 8-Br-cGMP on ET-1-induced 
ERK1/2, PKB and Pyk2 phosphorylation in A-10 VSMCs. Serum-starved 
quiescent A-10 cells were pretreated without or with the indicated 8-Br-cGMP 
concentrations for 15 min followed by 10 nM of ET-1 for 5 min. Cell lysates 
were immunoblotted by phospho-specific-Tyr204-ERK1/2 antibodies (A) and 
phospho-specific-Ser473-PKB antibodies (B), and phospho-specific-Tyr402-Pyk2 
antibodies (C), as shown in the top panels of each section. Blots were also 
analyzed for total ERK1/2, PKB and Pyk2 (middle panels of each section). 
Bottom panels (bar diagrams) in each section represent average data quantified 
by densitometric scanning of immunoblots. Values are the means  SE of at 
least 3 independent experiments and are expressed as percentage 
phosphorylation where phosphorylation observed with ET-1 alone is defined as 
100%. (A)     *P< 0.003 vs control, †P< 0.005 vs ET-1. (B) *P< 0.0001 vs 
control, †P< 0.0003 vs ET-1. (C) *P< 0.001 vs control, †P< 0.005 vs ET-1.  
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Figure 6. Effect of the inhibitor of the soluble guanylate cyclase, ODQ on ET-1-
induced ERK1/2, PKB and Pyk2 phosphorylation in A-10 VSMCs. Serum-
starved quiescent A-10 cells were pretreated without or with the indicated ODQ 
concentrations for 15 min before addition of 300 M SNAP for 15 min followed 
by 10 nM of ET-1 for 5 min. Cell lysates were immunoblotted by phospho-
specific-Tyr204-ERK1/2 antibodies (A), phospho-specific-Ser473-PKB antibodies 
(B) and phospho-specific-Tyr402-Pyk2 antibodies (C), as shown in the top panels 
of each section. Blots were also analyzed for total ERK1/2, PKB and Pyk2 
(middle panels of each section). Bottom panels (bar diagrams) in each section 
represent average data quantified by densitometric scanning of immunoblots. 
Values are the means  SE of at least 3 independent experiments and are 
expressed as percentage phosphorylation where phosphorylation observed with 
ET-1 alone is defined as 100%.   (A) *P< 0.0002 vs control, †P< 0.007 vs ET-1, 
‡ P< 0.002 vs SNAP + ET-1. (B) *P< 0.0002 vs control, †P< 0.0006 vs ET-1, ‡
P< 0.003 vs SNAP + ET-1. (C) *P< 0.0005 vs control, †P< 0.002 vs ET-1, ‡ P< 
0.02 vs SNAP +   ET-1. Section (D) shows the effect of ODQ on basal or on ET-
1-induced ERK1/2, PKB and Pyk2 phosphorylation.    
Figure 7 Effect of different concentrations of SNAP on ET-1-induced 
[3H]leucine incorporation into proteins. Serum-starved quiescent A-10 cells 
were pretreated with 10 and 100 M of SNAP for 30 min  before  ET-1 (10 nM) 
stimulation , then the cells were labeled to equilibrium with [3H]leucine for 20 h 
as described in Materials and Methods. Values are the means  SE of 3 
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independent experiments and are expressed as percentage of change in 
[3H]leucine incorporated into total cellular proteins over the basal values. *P< 
0.002 vs control, †P< 0.004 vs ET-1.  
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FIGURE 6 
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CHAPTER-5 
GENERAL DISCUSSION 
 
ET-1, the most potent vasoconstrictor peptide was discovered only 20 years ago. 
Although studies done during the last 2 decades have clarified the physiological and 
pathophysiological role of ET-1 in multiple systems, many questions in this field still 
remain unresolved.  
In the vascular system, ET-1 has a basal vasoconstriction role (tonic role) and an 
upregulated ET-1 system has been suggested among the contributing factors in to the 
development of vascular disease such as hypertension and atherosclerosis. ET-1 
contributes also to myocardial contractility, chronotropy and arrhythogenesis, as well as 
congestive heart failure, renal disorders and pulmonary diseases. Based on recent 
experimental data, treatment with newly available ET-1 antagonists is likely to inhibit 
ET-1-induced functional and structural alterations in the vasculature. However, a better 
knowledge of ET-1 signaling transduction pathways would be important for devising 
specific therapeutic agents directed against critical components of signaling systems 
implicated in vascular remodeling.  
ET-1 elicits its effects through the stimulation of its G-protein-coupled receptors (GPCR) 
which leads to the recruitment of multiple signaling pathways which includes protein 
kinases of the Raf family and lipid kinases of the phosphatidylinositol 3-kinase (PI-3K) 
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family. Both pathways are shown to be involved in cellular growth and proliferation two 
important phenomenons by which ET-1 triggers some of pathophysiological states. In 
parallel, it is also known that ET-1 increases intracellular Ca2+ concentration in many cell 
types including VSMCs and induces vascular contractility via the activity of Ca2+ and 
calmodulin (CaM) system. CaMKII is a multifunctional serine/threonine protein kinase 
which is believed to transduce the downstream effects of Ca2+/CaM.  A role of CaMKII 
in mediating various physiological functions in several systems and pathophysiological 
events in different cell types, such as VSMCs (405) and cardiomyocytes (207) has been 
suggested and in heart, ET-1-induced cardiomiocyte hypertophy has been linked to 
CaMKII activation (207). Recently, Tiel et al have suggested a proarrhythmic effect of 
CaMKII by showing that CaMKII activation is a part of arrhythmia mechanism of 
Timothy syndrome(406). Moreover, studies showing that inhibition of CaMKII by KN-
93 prevents arrhythmic activity in rabbit pulmonary veins (407), decreases early 
afterdepolarizations in rabbit heart (408) and improves vascular dysfunction in animal 
models of diabetes (222) or in Ang II-induced hypertension (221), suggesting that 
aberrant activation of CaMKII may be involved in these cardiovascular pathologies.
The involvement of CaMKII system in ET-1 induced signaling was not studied before, 
therefore we investigated the role of CaMKII in ET-1-induced ERK1/2, PKB and Pyk2 
signaling which are believed to be key players in mediating growth-promoting, 
proliferative, migratory, survival and death responses in the cell. In these studies, we used 
three different strategies: classical pharmacological inhibitors, transfection of cells with 
CaMKII inhibitory peptide (AA 281-309) corresponding to auto-inhibitory domain of 
CaMKII and finally use of small interfering RNA (siRNA) technique. These studies are 
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the first to report an activation of CaMKII by ET-1 in VSMCs in Fig.2 article 1. This 
finding supports the idea that CaMKII plays a role in ET-1-induced signaling in VSMC. 
We further confirm this idea by showning that CaMKII phosphorylation was required for 
ET-1-induced ERK1/2, PKB and Pyk2 phosphorylation in VSMC. We have also shown 
in these studies that ET-1 was able to induce an increase in both protein and DNA 
synthesis which is consistent with other studies done in VSMC. However, these studies 
are the first to report an inhibitory effect of both CaM and CaMKII antagonists on ET-1-
induced both growth and proliferation in VSMC which suggests a probable role of 
CaMKII in vascular diseases related to ET-1. Thus, CaMKII inhibition may be a good 
strategy to prevent or treat these pathologies.  
Several studies have indicated that ROS play an essential role in propagating the signals 
of many growth factors, peptide hormones and cytokines such as EGF, Ang- II (409) and 
tumor necrosis factor- (TNF-) (410). Increased ROS generation has been associated 
with a variety of cardiovascular pathologies including hypertension and atherosclerosis. 
In our laboratory, we have shown earlier that ROS is generated by ET-1 in VSMC and 
these ROS are needed to mediate ET-1-induced activation of ERK1/2, PKB, and Pyk2 
signaling as well as protein synthesis (10). We have also reported earlier a requirement of 
Ca2+ and CaM in H2O2-induced activation ERK1/2 and PKB (411). On  the other hand, 
CaMKII have been shown to be upstream of H2O2-induced ERK1/2 phosphorylation in 
endothelial cells (412). Thus, the contribution of CaMKII in H2O2-induced ERK1/2, PKB 
and Pyk2 in VSMC remains obscure and needs to be clarified. Therefore, in the second 
article of this thesis, we investigated the role of CaMKII in H2O2-induced ERK1/2, PKB 
and Pyk2 phosphorylation in VSMC and since we have shown earlier the ability of H2O2 
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to activate Pyk2 and IGF-1R (324), we extended these studies to examine the role of 
CaMKII in Pyk2 and IGF-1R phosphorylation induced by H2O2. Our results provided 
evidence that CaMKII is upstream of Pyk2 phosphorylation induced by H2O2 and also 
CaMKII phosphorylation is needed for H2O2 evoked IGF-1R transactivation in VSMCs. 
In this article we have shown a time course of H2O2 induced CaMKII phosphorylation 
(Fig.5 Article 2). This data shows for the first time a phosphorylation of CaMKII induced 
by H2O2 in VSMC. Overall, our data reveal that CaMKII serves as a critical upstream 
component in triggering the H2O2-induced signaling cascade resulting in the 
phosphorylation of IGF-1R, Pyk2, ERK1/2 and PKB in VSMC. It may be suggested that 
through the activation of these signaling events CaMKII contributes to the regulation of 
various cellular processes including cell growth, proliferation, hypertrophy and survival 
in VSMC. Dysregulation of CaMKII activity may thus play an important role in the 
pathogenesis of vascular disease. NO is another important free radical that has been 
shown to contribute to the regulation of several hormone-mediated responses such as 
attenuation of the proliferative stimulation of VSMCs and cardiac fibroblasts induced by 
EGF (387) and Ang II (413). It has been suggested that NO might exert these effects by 
modifying the growth-promoting signaling events. The support for this notion is provided 
from studies in which NO was shown to attenuate ras/ERK1/2 signaling in response to 
EGF (387) and Ang II (404) as well as PKB in response to PDGF (392). NO was also 
shown to attenuate Ang II-stimulated Pyk2 phosphorylation in cardiac fibroblasts (393). 
Recently, ET-1-induced cardiomyocyte hypertrophy also has been fund to be attenuated 
by NO through cGMP production (366). Despite the fact that a potential cross-talk 
between ET-1 and NO exists, and NO is believed to counteract the effects of ET-1, not 
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much information on the ability of NO to modify ET-1-induced signaling in VSMCs is 
available. The only study to investigate a role of NO in ET-1-induced responses in 
VSMCs was from Sand’s laboratory in which they have been investigating the effect of 
NO on ET-1-induced vascular contraction in human placental arteries. In these studies, 
they have reported an inhibitory effect of NO in arteries contraction induced by ET-
1(414).Therefore, in the present studies, we have investigated if NO generation would 
modify ET-1-induced signaling pathways involved in cell growth and proliferation. Our 
data indicated that addition of the NO donors, SNAP or SNP decreased the 
phosphorylation level of ERK1/2, PKB and Pyk2 induced by ET-1. On another hand 
inhibition of NO generation by a pretreatment with NO inhibitor, L-NAME, increases 
these responses.  These results are similar to previous studies in which Ang II-induced 
phosphorylation of ERK1/2 and Pyk2 was blocked by SNAP. This work represents the 
first detailed investigation on the effect of NO system on multiple signaling systems 
induced by ET-1 in VSMC. This study demonstrated that NO antagonizes ET-1-induced 
signaling in VSMC. Pyk2 has also been implicated in Ang II and ET-1-induced MAPK 
activation in cardiac fibroblasts and VSMC. Thus, it is possible that Pyk2 serves as an 
upstream mediator of MAPK cascade induced by ET-1 in A-10 VSMC. In these studies, 
we have also shown that A10 VSMC express eNOS as compared to endothelial cells 
which support our finding by detecting the source of NO in these cells. 
We have also demonstrated a role of cGMP in mediating the attenuating effect of NO on 
ET-1 signaling pathway by using 8-Br-cGMP. The results showed that 8-Br-cGMP 
decreased ERK1/2, PKB and Pyk2 phosphorylation induced by ET-1and it thus 
mimicked the inhibitory effect of SNAP and SNP. We further evaluated an involvement 
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of soluble guanylate cyclase by using a specific inhibitor, ODQ, and demonstrated that it 
could reverse the inhibitory effect of SNAP on ET-1-induced ERK1/2, PKB and Pyk2 
phosphorylation. It has been previously shown that ODQ can block SNAP-induced 
elevation in cGMP levels in rat aortic VSMC (415), endothelial cells (367) and 
cardiomyocytes (416). Finally, we also provide evidence showing that ET-1-stimulated 
protein synthesis, a hallmark of hypertrophic response, is also attenuated by NO donor, 
SNAP.  
 
Taken together, we demonstrate that NO inhibits the ET-1-stimulated increase in the 
phosphorylation state of ERK1/2, PKB and Pyk2 in A-10 VSMC. Since ERK1/2, PKB 
and Pyk2 plays a crucial role by mediating VSMC growth and hypertrophy, it may be 
suggested that the ability of NO to attenuate these pathways may serve as a potential 
mechanism by which NO counteracts the biological responses of ET-1. 
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CHAPTER-6 
Conclusion and Perspectives 
Overall, the studies presented in this thesis (Fig. 13) demonstrate that CaMKII activation 
is needed for both ET-1 and H2O2 (which is known to play an essential role in 
propagating the signals of ET-1) -induced phosphorylation of ERK1/2, PKB and Pyk2. 
Also our work demonstrates a critical role of CaMKII in mediating H2O2-induced IGF-
1R transactivation in VSMCs. On the other hand, we have demonstrated that NO 
antagonizes ET-1-induced activation of above signaling pathways. Finally, we have 
demonstrated that CaMKII activation and NO generation have opposite effect on 
hypertrophic and proliferative responses induced by ET-1 in VSMCs which are 
associated to several cardiovascular diseases. The results presented in this thesis have 
uncovered a key upstream role of CaMKII in triggering ET-1 and H2O2-induced signaling 
events in VSMC.  The results presented in this thesis highlight the protective role of NO 
and the pro-pathogenic role of CaMKII in vasculature. Since both NO and CaMKII are 
involved in ET-1-induced signaling pathways and since both of these components are 
Ca/CaM dependent, it will be important to test the effect of NO on ET-1-induced 
CaMKII activation as well as its effect on ET-1 and H2O2-induced growth factor 
receptors transactivation because role of NO in growth factor receptors transactivation 
has not been studied before. Clarifying these points will help us to better understand the 
vasoactive peptide and redox-induced signaling in VSMCs.  
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Fig.13. A model summarizing mechanism by which  ET-1 and H2O2-induced signaling in 
VSMC with implication of CaMKII and NO. 
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